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Dedication 
 
While reading through survey responses, I came across one that just stopped me.  
It is just a simple thing, but it was something my mom always tells me.  The participant 
had responded to a question, which asked them to give advice to those who will find out 
they are BRCA1/2 positive in the future.  She wrote: “I would tell them to breathe. 
Knowledge is power and knowing is such a blessing. Many people will never know that 
they will get cancer. This is such a blessing to those who can know and do something 
about it.” 
This response reminded me so much of something my mom would say to me.  
So—I dedicate my thesis project to my mom, the lady who made me breathe and 
remember the blessings I do have throughout the writing of this thesis.  In addition, I 
would like to dedicate this to anyone who is BRCA1/2 positive.  There is so much we 
could all learn from the strength and kindness of the amazing women I encountered 
through the collection of this data you are about to see.   
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Abstract 
Objective: To examine if BRCA1/2 mutation carriers who received their positive genetic 
test result by age 25 were satisfied with their decision to undergo genetic testing and with 
the choices made regarding family planning, surveillance, and surgery.  Methods: 72 
participants recruited via social media completed a survey hosted by SurveyMonkey.com.  
Sixty-three met study criteria and were asked 40 quantitative and qualitative questions 
designed to assess family planning, surveillance, and surgery needs of young BRCA 
carriers, which included a six question Satisfaction with Decision Scale.  Results: 
Regardless of age, participants were very satisfied with the decision to undergo genetic 
testing.  Recommendations were made for the counseling and care of BRCA1/2 mutation 
carriers under age 25, which included: (1) Right Reproductive Organs, (2) Risk Reducing 
Mastectomy, (3) Risk Figures, (4) Reproductive Options, and (5) Resource for Future.  
Conclusions: Participants desired more clear and unbiased care and counseling, where 
they felt supported.  The complexity of HBOC plus the variable lives BRCA1/2 positive 
emerging adults face led us to propose a core set of counseling recommendations for 
young BRCA mutation carriers under age 25.  Incorporating the five recommendations is 
essential to achieving full patient autonomy and unbiased decision facilitation. 
 
 
 
Keywords: cancer, oncology, BRCA1/2, genetic testing, testing satisfaction, 
emerging adults  
vi 
 
 
Table of Contents  
Dedication.......................................................................................................................... iii 
Acknowledgements.............................................................................................................iv 
Abstract................................................................................................................................v 
List of Tables ................................................................................................................... viii 
List of Figures.....................................................................................................................ix 
Chapter 1: Background ........................................................................................................1 
 1.1 BRCA1 and BRCA2 basics.................................................................................1 
1.2 Targeting Individuals who Tested BRCA1/2 Positive as Emerging Adults ......3 
1.3 The Risks Faced by Mutation Carriers Before Age 25......................................7 
1.4 Need for Targeting BRCA1/2 Positive Emerging Adults ................................12 
Chapter 2:  I Wish I Had Known This! Impact of Age on Life Choices and Testing  
Satisfaction for BRCA1/2 Mutation Carriers who Underwent 
Genetic Testing By Age 25................................................................................................14 
 2.1 Abstract............................................................................................................14 
 2.2 Introduction .....................................................................................................15 
 2.3 Materials and Methods ....................................................................................21 
vii 
 2.4 Results..............................................................................................................26 
 2.5 Discussion........................................................................................................54 
 2.6 Conclusions .....................................................................................................64 
Chapter 3: Conclusions .....................................................................................................66 
References..........................................................................................................................68 
Appendix A: List of Social Media Sources Contacted and/or Utilized ............................73 
Appendix B: Templates for Correspondence with Social Media Groups ........................74 
Appendix C: Participant Survey ........................................................................................83 
Appendix D: Advice from one BRCA1/2 Positive Women to Another...........................104 
Appendix E: Additional Results ......................................................................................107 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
 
List of Tables 
Table 2.1 Participant characteristics and demographics....................................................28 
Table 2.2 SWDS questions and response options .............................................................29 
Table 2.3 SWDS and age at time of study.........................................................................29 
Table 2.4 SWDS vs. participant demographics and life planning choices........................30 
Table 2.5 Participants’ experiences and life planning choices related to BRCA ..............32 
Table 2.6 Participants level of worry or concern regarding life events (%)......................33 
Table 2.7 Surgical choices and decisions made.................................................................36 
Table 2.8 Life experience and outlook ..............................................................................38 
Table 2.9 Screening plans and thoughts on the options available .....................................44 
Table 2.10 Healthcare and support related to being BRCA1/2 positive ............................45 
Table 2.11 Participant education vs. life planning choices or age at time of study.........108 
Table 2.12 Personal income vs. life planning choices or age at time of study................108 
Table 2.13 Participant ages by group vs. life planning choices.......................................108 
Table 2.14 Participants who received genetic counseling vs. life planning ....................109 
Table 2.15 Genetic testing results disclosure ..................................................................110 
 
 
 
 
ix 
 
 
List of Figures 
Figure 2.1 Criteria for study participation .........................................................................26 
Figure 2.2 Participant ages at the time of study.................................................................26 
Figure 2.3 Healthcare services rated by their provision of support and guidance.............34 
Figure 2.4 Participants’ BRCA1/2 status as pressure to speed up or slow down life ........49 
Figure 2.5 Participants’ opinions on family planning options...........................................51 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
 
List of Abbreviations 
ANOVA....................................................................................... Analysis of Variance Test 
BRCA1 ................................................................................................Breast Cancer Gene 1 
BRCA2 ................................................................................................Breast Cancer Gene 2 
BSO..................................................................................Bilateral Salpingo Oopherectomy 
CBE..................................................................................................... Clinical Breast Exam 
HBOC ...................................................................... Hereditary Breast and Ovarian Cancer 
IVF....................................................................................................... In-Vitro Fertilization 
NSGC..................................................................... National Society of Genetic Counselors 
PBM...............................................................................Prophylactic Bilateral Mastectomy 
PBO ...........................................................................Prophylactic Bilateral Oopherectomy 
PGD ............................................................................. Pre-implantation Genetic Diagnosis 
SWDS ................................................................................Satisfaction with Decision Scale 
 
 
 
 
 
1 
 
 
 
Chapter 1: Background 
1.1 BRCA1 and BRCA2 Basics  
Cancer is a major health problem in many countries.  In the United States, it causes one 
in four deaths.  In 2012, there were 229,060 new cases of breast cancer.  Of these, 
226,870 were females and 2,190 were males.  Breast cancer was the cause of 39,920 
deaths.  Of these deaths, 39,510 were females and 410 were males.  Ovarian cancer was 
reported in 22,280 new cases and 15,500 deaths. (Siegel, Naishadham, & Jemal, 2013).   
Breast and ovarian cancer are not unusual in the general population.   One in 
eight, or 12.5% of women will develop breast cancer over their lifetime while one to two 
in one hundred, or 1-2% of women will develop ovarian cancer.  The average risk for 
cancer gradually increases over one’s lifetime (Petrucelli, Daly, & Feldman, 2011).  
While a majority of cancers are sporadic or randomly occurring, about 10% of all breast 
and ovarian cancer cases are hereditary, or passed down though families.   
Individuals with hereditary cancer have a higher risk of developing cancer than 
individuals in the general population.  Hereditary cancer is due to germline mutations, or 
genetic changes that are passed down from parent to child.  Among the individuals that 
fall within this hereditary breast cancer susceptibility group, 35% of cases will be due to a 
mutation in the BRCA1 gene while 37% of cases will be due to a mutation in the BRCA2 
gene.  Among those in the hereditary ovarian cancer susceptibility group, 80% will have 
a BRCA1 mutation and 15% will have a BRCA2 mutation.  The remaining cases are due 
to other genes or unknown causes (Clark & Domchek, 2011; Ford, et al., 1998).   
2 
 BRCA1 and BRCA2 are the two genes that cause the genetic condition known as 
Hereditary Breast and Ovarian Cancer Syndrome (HBOC).  HBOC is a hereditary cancer 
predisposition syndrome that is caused by mutations or changes in one of these two 
genes.  Each gene has two alleles, or copies.  One is passed on from the father and one is 
passed on from the mother.  Receiving a mutated copy of one of these genes from either 
parent can increase an individual’s risk for various types of cancer. In nearly all cases, 
these mutations are passed down in families.  Very few de novo, or randomly occurring 
mutations in these genes have been reported. The incidence of de novo mutations in 
either the BRCA1 or the BRCA2 gene is thus unknown.   
HBOC syndrome is inherited in an autosomal dominant fashion, meaning that just 
one mutated copy of the BRCA1 gene or the BRCA2 gene will cause this predisposition 
that may lead to cancer. If a parent has a mutated copy, each child has a 50% risk of 
inheriting the mutated copy of the gene.  The highest cancer risk is for breast or ovarian 
cancer, but other cancers such as pancreatic, prostate, or fallopian tube cancer can result.  
A slight yet increased risk has been found for melanoma in BRCA2 carriers and for 
endometrial cancer in BRCA1 carriers (Clark & Domchek, 2011; Segev et al., 2013). 
 The overall prevalence of BRCA1 and BRCA2 mutations in the general population 
is between 1/400 and 1/800 individuals.  The incidence depends on ethnicity.  The 
highest incidence is seen in the Ashkenazi Jewish population.  The incidence is 1/40 
primarily due to three common founder mutations, 187delAG and 5385insC for BRCA1 
and 6174delT for BRCA2.  Dutch and Icelandic populations also have a higher incidence 
of BRCA1 or BRCA2 gene mutations (Petrucelli et al., 2011). 
3 
There are differences in lifetime cancer risk for women depending on whether 
they carry a mutation in the BRCA1 or the BRCA2 gene.  On average, 60-70% of women 
with a BRCA1 gene mutation will develop breast cancer by the age of 70, while an 
average of 40% will develop ovarian cancer, which includes fallopian tube and primary 
peritoneal carcinomas.  For women with a BRCA2 gene mutation, an average of 45-55% 
of women will develop breast cancer by age 70 while 20% will develop ovarian cancer.  
Women also have an increased risk for other cancers such as pancreatic cancer or 
melanoma (Clark & Domchek, 2011).  The highest risk for these two types of cancer in 
women is thus associated with a BRCA1 gene mutation (Petrucelli et al., 2011). Women 
have up to a 10% risk of pancreatic cancer as well (Ford, et al., 1998).   
Males with a BRCA2 gene mutation have up to an 8% risk of developing breast 
cancer.  Those with a BRCA1 mutation have up to a 1% risk (Petrucelli et al., 2011; 
Shiloh, Dagan, Friedman, Blank, & Friedman, 2013).  Males have up to a 2-6% risk of 
gastric and pancreatic cancer, with the highest risk being for males with a BRCA2 gene 
mutation.  Men have a slightly increased risk for prostate cancer over that of the general 
population (Shiloh et al., 2013).  The age of cancer onset is similar to that of sporadic 
breast cancers in the general population with BRCA2 mutations (Ford et al., 1998).  
1.2 Targeting Individuals who Tested BRCA Mutation Positive as Emerging Adults 
  Individuals who are between the ages of 18 and 24 are in a highly transitional 
period of their lives now known as emerging adulthood.  Emerging adulthood, a phrase 
coined in 2000 by Arnett, describes a unique demographic period that pertains to the 
exploration of one’s identity through the postponement of adulthood.  Young, BRCA 
mutation positive individuals are potentially making major choices and decisions that will 
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impact their lives for years to come.  These decisions can include career, significant 
other, family planning, and geographic location choices. By the late 20s, a majority of 
individuals have made decisions in their lives that will have lasting consequences.  
Further, when adults retrospectively considered the most crucial events in life, they 
mainly cited events in this period (Arnett, 2012).  
 As a result of these fast-paced changes and choices, researchers have started to 
examine if having a BRCA1 or BRCA2 gene mutation impacts this tumultuous time in life 
(e.g. Hoskins, Werner-Lin, etc.). Individuals who fit into this emerging adulthood group 
and who are from families with an identified BRCA1/2 gene mutation may base decisions 
regarding normal life transitions upon a timeline of when they expect illness to occur.  
Anxiety, worry, and grief regarding disease have been found to play an underlying role in 
this transitional era in life when hereditary cancer is an issue (Werner-Lin, 2007).   
There is much research that still needs to be done for this critical demographic 
group, because the current professional medical guidelines available to young, BRCA 
positive individuals suggest genetic testing be made available when they reach the age of 
eighteen (Trepanier et al., 2004). However, this recommendation is based on the principle 
that individuals of this age can now act as autonomous adults.  Though they are able to 
make informed decisions about their own risks and genetic testing, the true autonomy is 
debatable.  For young, high-risk individuals of this age group, autonomous decision-
making is one of the milestones in development that may not yet be reached (Arnett, 
2000).  Many individuals in this age group may still live at home, at least part time, and 
still be dependent on their parents or guardians for support.  This support could range 
from financial support to facilitating their child’s decision-making processes. 
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The major concern is that young, BRCA positive individuals may experience 
greater harm and lesser benefits to their psychosocial well-being when learning about 
their BRCA1/2 mutation carrier status.  Compared to individuals older than 25, 
individuals diagnosed with a BRCA1/2 gene mutation as emerging adults may find that 
there are fewer concrete recommendations for them to utilize once they know their status.  
With or without the support of their family members or other health care providers, the 
decision-making processes that young, BRCA positive individuals undertake are distinct 
from individuals of the same age in the general population.  This age group is also unique 
from all other individuals who are a part of the overall group of families with HBOC.  
Young mutation carriers know they are BRCA positive by age 25, but there is little 
published data on what actions to take regarding this life-changing information.   
In two related studies, it was determined that complex decision making processes 
evolve over time.  The ability to fully understand and act on newly discovered genetic 
information and to make confident, life-altering decisions is still developing in this 
period.  Therefore, it will be critical to have support and guidance at this point in the life 
cycle to assure young, BRCA positive individuals make autonomous, informed choices 
where they fully understand both the benefits and risks of knowing one’s mutation status. 
This study suggested that it would be critical to have concrete goals to model decision-
making upon, as well as resources from providers who will deliver the genetic education 
and information to this age group.  Support and guidance to assure young, BRCA positive 
individuals are making autonomous, informed choices and fully understand the benefits 
and risks of knowing one’s mutation status is key (Werner-Lin, Hoskins, Doyle, & 
Greene, 2012).  Specifically, these young BRCA mutation carriers report a desire for 
6 
clearer screening guidelines and continuing support regarding their medical care over 
time, as their life and needs evolve (Hoskins, Werner-Lin, & Greene, 2014).  
In another study pertaining to women who are 18-24 years old, Patenaude et al. 
(2013) looked at levels of concern and knowledge about hereditary cancer in young 
women who have BRCA1 or BRCA2 positive mothers.  They found that one third of the 
daughters reported high cancer-related distress, even though they had expressed normal 
levels of general distress.  Knowing this genetic information about their mothers raised 
concerns for their futures, especially in regards to having children.  The level of 
knowledge about HBOC was suboptimal with many misconceptions about their risk for 
carrying a BRCA mutation.   This indicated that future studies could be vital in 
determining how young, BRCA positive women are coping after they undergo genetic 
testing themselves and also test positive for a BRCA1 or BRCA2 gene mutation.  
This study collected data from several different, industrialized countries that may 
inform individuals and health providers in similarly industrialized countries.  Delaying 
marriage and childbearing in favor of gaining an education first is increasing among 
industrialized countries.  Individuals from industrialized countries in this age range may 
experience comparable dilemmas. This is because emerging adulthood is not a universal 
developmental period, but a stage in life seen only in cultures that postpone entry into 
adult responsibilities until individuals are in their early to mid twenties (Arnett, 2000).  
1.3 The Risks Faced by BRCA Mutation Carriers By Age 25 
 Females and males under age 25 are at a low risk to developing cancer.  Even 
though breast cancer is the leading cause of cancer death among women, breast cancer 
does not make the top five leading causes of cancer-related deaths in women under age 
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20 (Siegel et al., 2013).  For young BRCA1/2 gene mutation carriers, the relative risk at 
this time may seem higher.  Particularly since their absolute risk or lifetime risk for 
cancer is significantly higher than other women in the general population.  
In actuality, young BRCA1/2 carriers have a small chance to develop an HBOC 
related cancer before age 30.  The risk for developing breast cancer before age 30 is 
about 4.6% for women who carry a BRCA1/2 mutation (Ford et al., 1998) while the risk 
for developing ovarian cancer is nearly zero (Stratton et al., 1999).  Between the ages of 
20 to 24, the risk is even lower.  It is estimated that the incidence for BRCA1 and BRCA2 
mutation carriers is .02% for breast cancer and .001% for ovarian cancer (Antoniou et al., 
2003).  While these numbers are low, BRCA1 and BRCA2 mutation carriers between the 
ages of 20 and 29 still have a relative risk to have breast cancer that is 5 to 20 times 
higher then a woman of the same age in the general population (Clark & Domchek, 
2011).  For males, the risk of developing cancer is even lower.  Male cancer risk typically 
does not start until age 40 (Shiloh et al., 2013).   
The looming lifetime risk for cancer may drive many young individuals to 
undergo genetic testing earlier then some guidelines suggest (Ormondroyd et al., 2012).  
This is because individuals who are 18 to 24 years in age do not yet have a fully 
developed frontal lobe of their brain, leading them to have impaired judgment, morality, 
and abilities to make long-term plans.  This time in life is still a critical period in the 
development of the human brain (Steinberg, 2005).  Young mutation carriers may feel 
life is now like a waiting game, or that they are a ticking cancer bomb, even though the 
actual risk for developing cancer is not inevitable (Kwong & Chu, 2012). Young, BRCA 
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positive individuals may act as though cancer development will be experienced in the 
near future even though this is improbable (Hoskins & Warner-Lin, 2012).     
 While these fears may push some young carriers to consider surgical treatment or 
risk-reducing drug options.  Many surgeons fear that these decisions may cause regret for 
young, BRCA positive individuals later in life.  Surgeons may be cautious to remove 
seemingly healthy breast and especially ovarian tissue from women in this young age 
group due to the risks associated with these major surgeries such as pain syndromes and 
body image issues, even if they do carry a genetic mutation (Kwong & Chu, 2012).  
Young, BRCA positive individuals may seek advice from their primary health care 
providers, surgeons, or gynecologists.  Many health care providers are unlikely to be 
trained to handle the sensitive nature of topics related to BRCA for this age group.  
Unlike many other mutation positive individuals, young, BRCA positive individuals’ 
surgical decisions cannot be made quickly.  This group needs support to assure that they 
have considered all facets related to their decision and its potential ramifications, since 
they are less likely be mature when making independent decisions and acting 
autonomously (Werner-Lin, Hoskins, Doyle, & Greene, 2012).   
 Despite the low risks of developing cancer, young, BRCA positive individuals 
may continue to face anxiety and fear once they know their carrier status.  Genetic 
counseling and care for young, BRCA positive individuals involve considering 
psychosocial adaptation and risk management like all other patients.  This group is 
unique in the sense that the traditional options given to individuals, such a surgical 
choices and reproductive planning, may not seem to apply at the time of genetic test 
result disclosure.  Reproductive issues and surgical options are related topics however.  
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Thus, they may be highly appropriate subjects for young carriers to learn of in a genetic 
counseling session, since they may not have begun or completed their families (Kwong & 
Chu, 2012; Ormondroyd et al., 2012). 
While young, BRCA positive individuals may be hesitant to learn all of this 
information; basic knowledge will be key for future decisions.  The ability to carefully 
think ahead and plan for the future is a rare opportunity this group has, where compared 
to older BRCA carriers.  The sensitive and complex nature of these BRCA-related topics 
as well as the likelihood that they will have an impact on each individual’s life requires 
careful discussion with trained health care providers to navigate through possible issues 
(Ormondroyd et al., 2012).  Otherwise, there is a possibility that young, BRCA positive 
individuals may experience distress regarding having genetic testing or the choices that 
they have made based on their BRCA1/2 positive status. 
 Emerging adults in this high-risk group can be made aware of recommended 
options for surveillance, chemoprevention, and prophylactic surgery.  All surveillance 
guidelines state that mutation positive individuals should start formal surveillance at the 
age of 25 or older.  Guidelines also suggest that high-risk individuals could start 
screening or surveillance as many as 10 years prior to the earliest age of diagnosis in their 
family.  Although for some families, this age still may not fall before 25 years of age, 
continuing to leave young, BRCA positive individuals without concrete options.   
When reviewing core guidelines for high-risk individuals, it is clear why this 
group feels worried and confused about what they should do with this knowledge 
regarding their genetic make-up  (Werner-Lin, Hoskins, Doyle, & Green, 2012).  
Recommendations bypass this group.  It is recommended that annual mammograms and 
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breast MRIs should begin at the age of 25.  Clinical breast exams (CBE) should be done 
annually or bi-annually starting at age 25, which can include high-risk men (Berliner, 
Fay, Cummings, Burnett, & Tillmanns, 2013).  Men are often suggested to wait until the 
age of 40 since they are at a lower overall risk for breast cancer (Shiloh et al., 2013).  At 
the age of 30, women can elect to have CA-125 screening and transvaginal ultrasounds to 
screen for ovarian cancer, even though the utility has yet to be proven for these tools.  At 
age 40, colorectal cancer screening via colonoscopies and PSAs for prostate cancer 
should be performed yearly (Berliner, Fay, Cummings, Burnett, & Tillmanns, 2013).     
Chemoprevention may be considered, and there are several options for women.  
Oral contraceptives may be recommended, and have been known to decrease the risk of 
ovarian cancer up to 45-60% if used over a period of five years in high-risk women who 
have a history of ovarian cancer (Berliner et al., 2013).  Medications such as tamoxifen or 
other chemopreventive drugs reduce the risk of developing breast cancer as well.  In a 
study of women who have an increased risk for breast cancer either because of family 
history or because their age greater then 60, tamoxifen reduced the risk for invasive 
breast cancer by 49%.  It also reduced the risk for women 49 and younger by 44% 
(Fisher, et al. 1998).   
There are also two main risk-reducing surgical options for women.  A risk 
reducing bilateral mastectomy may be considered.  This surgery reduces the risk of breast 
cancer by at least 90%.  There is no standard age for which this is recommended.  In 
addition, this more aggressive treatment through a surgical procedure may be more 
strongly considered if the patient has limited access to knowledgeable physicians, 
chemotherapeutic drugs, and surveillance equipment, such as MRI machines.  A risk-
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reducing bilateral salpingo oophorectomy (BSO) can also be performed.  This reduces the 
risk for ovarian cancer by 80-96% and reduces the risk of breast cancer by up to 50% in 
women who have not yet gone through menopause.  This is because hormone levels in 
young, BRCA positive women will drop following the removal of their ovaries, resulting 
in a decrease in the hormones present that would fuel cancer growth.  This surgery is 
recommended for women between the ages of 35 to 40.  This surgery will cause women 
to enter early menopause.  There are currently no guidelines and little data regarding 
chemoprevention or prophylactic surgeries for high-risk men (Berliner et al., 2013).  
 Since all of these options are recommended for those ages 25 and older, young 
individuals in this group may feel helpless in regard to taking control of their health.  For 
some, the fear of developing cancer may lead them to proceed with some of these 
treatments or surgeries.  For others, the concept of the waiting game may seem all too 
familiar (Hoskins & Werner-Lin, 2012).  No matter what path is taken, we aim to better 
understand the rationale and thought processes for young, high-risk individuals though 
this study.  The hope is that others’ experiences will better aid the young, BRCA1/2 
positive individuals of tomorrow.    
1.4 Need for Targeting BRCA1/2 Positive Emerging Adults 
According to guideline recommendations, this group of individuals between the 
age of 18 and 24 are the youngest candidates for BRCA1 and BRCA2 testing.  While 
young, BRCA positive individuals have a low risk for cancer during this time in life, 
BRCA mutation positive individuals still feel as though they are at high relative risk for 
receiving a cancer diagnosis.  They may find themselves in a dilemma as far as their risk 
management.  There is a significant lack of data for individuals who underwent genetic 
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testing at this age.  Previous work has shown that high risk women who carry a BRCA1/2 
gene mutation are satisfied with undergoing genetic testing and would recommend testing 
to others who are at high risk for breast cancer (Klemp, O’Dea, Chamberlain, & Fabian, 
2005).  The concern for these BRCA1/2 positive emerging adults is what to do after the 
genetic test results are disclosed.  There are essentially no guidelines for how they should 
manage their cancer risks, make life choices, or be counseled regarding reproductive and 
surgical options (Hoskins & Werner-Lin, 2012).   
Our study gathered information from individuals who received their positive 
genetic test result by age 25, in order to provide information to service providers working 
with individuals of this age group who have a known positive mutation status.  
Information obtained is intended as a useful resource that may make it possible for health 
care professionals and genetic counselors to better care for and understand this unique 
group of individuals.  This information may aid in generating better support and guidance 
for individuals of this often overlooked age (Hoskins & Werner-Lin, 2012).      
This study built on a small but growing collection of literature regarding emerging 
adults with a BRCA1/2 mutation.  There has been success with similar studies in the 
recent past.  The population was not as geographically diverse and the sample size was 
smaller. This study offered participants the opportunity to participate in a fully internet-
based survey method.  This unique study format, when compared to previous works, 
enabled us to reach more young mutation carriers (Hoskins, & Werner-Lin, 2012, 
Hoskins et al., 2014; Werner-Lin et al., 2012).  
We hypothesized that individuals who obtained their positive genetic test result 
by age 25 would be satisfied with their decision to undergo testing as well as with the 
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choices they have made regarding surveillance and surgery.  Further study objectives are 
below.    
 Comparisons will be made between participants under the age of 25 and participants 
age 25 or older at the time of study but had their positive genetic test result by age 25 
(Ford et al., 1998; Steinberg, 2005; Werner-Lin et al., 2012) 
o We predicted participants under 25 will be less satisfied. 
o We predicted participants under 25 would feel their timeline for life is more 
affected. 
 Life instability was analyzed (i.e., more residency changes/shorter relationships)  
(Ford et al., 1998; Hoskins, Roy, Peters, Loud, & Greene, 2008) 
o We predicted less satisfaction with undergoing genetic testing. 
o We predicted timeline for life and overall life plans would feel more effected.  
 Different Types of Metaphors (Comparisons between otherwise unrelated things)  
 Have seen and find the role of a genetic counselor important 
o More satisfied with their decision to have genetic testing 
o Timeline for life and overall life plans feels unaffected by HBOC  
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Chapter 2:  I Wish I Had Known This! Impact of Age on Life Choices and Testing 
Satisfaction for BRCA1/2 Mutation Carriers who 
 Underwent Genetic Testing By Age 25.1 
2.1 Abstract 
Objective: To examine if BRCA1/2 mutation carriers who received their positive genetic 
test result by age 25 were satisfied with their decision to undergo genetic testing and with 
the choices made regarding family planning, surveillance, and surgery.  Methods: 72 
participants recruited via social media completed a survey hosted by SurveyMonkey.com.  
Sixty-three met study criteria and were asked 40 quantitative and qualitative questions 
designed to assess family planning, surveillance, and surgery needs of young BRCA 
carriers, which included a six question Satisfaction with Decision Scale.  Results: 
Regardless of age, participants were very satisfied with the decision to undergo genetic 
testing.  Recommendations were made for the counseling and care of BRCA1/2 mutation 
carriers under age 25, which included: (1) Right Reproductive Organs, (2) Risk Reducing 
Mastectomy, (3) Risk Figures, (4) Reproductive Options, and (5) Resource for Future.  
Conclusions: Participants desired more clear and unbiased care and counseling, where 
they felt supported.  The complexity of HBOC plus the variable lives BRCA1/2 positive 
emerging adults face led us to propose a core set of counseling recommendations for 
young BRCA mutation carriers under age 25.  Incorporating the five recommendations is 
essential to achieving full patient autonomy and unbiased decision facilitation. 
_______________________ 
1 King, S. E., Brooks, K. A., Werner-Lin, A., & Herzog, T.  To be submitted to Psycho-Oncology.
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2.2 Introduction  
About 10% of individuals with breast and ovarian cancer will have a hereditary cancer 
predisposition, which can be passed down in their family.  Thirty-five percent of BRCA 
carriers will have a mutation in the BRCA1 gene while 37% will have a mutation in the 
BRCA2 gene, resulting in a genetic condition called Hereditary Breast and Ovarian 
Cancer Syndrome (HBOC).  The highest cancer risks are for breast or ovarian cancer.   
HBOC syndrome is inherited in an autosomal dominant fashion, meaning that one 
mutated copy of the BRCA1 or the BRCA2 gene will cause a predisposition for cancer.  
Mutation carriers have a 50% chance to pass on their BRCA mutation to their offspring. 
The prevalence of these BRCA1 and BRCA2 mutations in the general population is 
between 1/400 and 1/800.  It is higher in specific ethnic groups (Petrucelli et al., 2011). 
The incidence of de novo mutations in either gene is rare and still unknown (Antoniou et 
al., 2003; Clark & Domchek, 2011; Ford et al., 1998). 
On average, 60-70% of women with a BRCA1 gene mutation will develop breast 
cancer by the age of 70, while an average of 40% will develop ovarian cancer, which 
includes fallopian tube and primary peritoneal carcinomas.  For women with a BRCA2 
gene mutation, an average of 45-55% of women will develop breast cancer by age 70 
while 20% will develop ovarian cancer. A lesser yet increased risk has been found for 
other cancers, such as pancreatic cancer and melanoma for BRCA2 carriers or 
endometrial for BRCA1 carriers (Clark & Domchek, 2011; Segev et al., 2013). 
Females who carry a BRCA mutation have a low risk of developing cancer under 
age 25.  The risk for developing breast cancer before age 30 is about 4.6% (Ford et al., 
1998) while the risk for developing ovarian cancer before age 30 is nearly zero (Stratton 
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et al., 1999).  Between the ages of 20 to 24, the risk is lower.  It is estimated that the 
incidence for BRCA1/2 mutation carriers is .02% for breast cancer and .001% for ovarian 
cancer (Antoniou et al., 2003).  Despite these numbers, BRCA1/2 mutation carriers 
between the ages of 20 and 29 have a relative risk of breast cancer 5 to 20 times higher 
than that of women of the same age in the general population (Clark & Domchek, 2011).   
The individuals targeted by this study who underwent genetic testing by age 25 
are among the youngest genetic testing consumers for BRCA1 and BRCA2 single gene 
testing.  While young, BRCA positive individuals have a low risk for cancer during this 
time in life, they may still feel as though they are at high risk for receiving a cancer 
diagnosis and may be unsure how to proceed with risk management. Few guidelines 
outline empirically-based risk management strategies (Trepanier et al., 2004), much less 
how to support life choices, and be optimally counseled regarding medical management 
(Hoskins & Werner-Lin, 2012; Hoskins et al., 2014).   
The looming lifetime risk for cancer may drive many young individuals to 
undergo genetic testing earlier then some guidelines suggest (Ormondroyd et al., 2012).  
However, individuals who are 18 to 24 years of age do not yet have a fully developed 
frontal lobe of their brain, leading them to have judgment and morality that is not fully 
developed (Steinberg, 2005).  They are also in a transitional period in life, between ages 
18 and 25, known as emerging adulthood.  This unique demographic period is when 
individuals explore their own identity through the postponement of an adult lifestyle.  
Young BRCA mutation-positive individuals are potentially making major choices and 
decisions that will impact their lives for years to come.  Decisions can include career, 
significant other, family planning, and geographic location choices. By the late 20s, most 
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individuals have made decisions with lasting consequences.  When adults retrospectively 
consider key life events, they mainly cite this period as a critical time when life-shaping 
decisions were made (Arnett, 2012).  
 Researchers have examined how having a BRCA1/2 gene mutation impacts this 
tumultuous time in life (e.g. Hoskins, Werner-Lin, etc.) and shapes future life for young, 
BRCA positive emerging adults (Arnett, 2000). Individuals who are emerging adults and 
also from families with an identified BRCA1 or BRCA2 gene mutation may base 
decisions regarding normal life transitions upon a timeline of when they expect illness to 
occur.  Anxiety, worry, and grief regarding disease were found to have an underlying role 
in shaping cancer risk perception at this young age (Werner-Lin, 2007).   
Current professional medical guidelines available to young, BRCA positive 
individuals suggest genetic testing be made available when they reach the age of eighteen 
(Trepanier et al., 2004).  Previous research has shown that high-risk women who carry a 
BRCA1/2 gene mutation are satisfied with undergoing genetic testing and would 
recommend testing to others at high risk for breast cancer (Klemp et al., 2005).  
However, the concern for these BRCA1/2 positive emerging adults is what to do after the 
genetic test results are disclosed.  Young, BRCA positive individuals may experience 
greater harm and fewer benefits when learning about their BRCA1/2 mutation carrier 
status.  Compared to individuals older than 25, fewer concrete recommendations exist for 
known carriers under age 25.  The decision-making processes young mutation carriers 
undertake are distinct from older BRCA carriers since there is little published data to 
guide what do with this powerful, personal genetic information.   
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Support and guidance to assure young, BRCA positive individuals are making 
autonomous, informed choices and fully understand the benefits and risks of knowing 
one’s mutation status is key (Werner-Lin et al., 2012).  Specifically, these young BRCA 
mutation carriers desire clearer screening guidelines and continuing support regarding 
their medical care over time, as their life and needs evolve (Hoskins et al., 2014).  
Patenaude et al. found that one third of the daughters of known BRCA1/2 carriers 
reported high cancer-related distress, especially in regards to childbearing.  The level of 
knowledge about HBOC was suboptimal with many misconceptions about their risk for 
carrying a BRCA mutation (2013).     
Young, BRCA positive individuals may feel life is now like a waiting game, or 
that they are a ticking cancer bomb, even though the actual risk for developing cancer is 
low (Kwong & Chu, 2012).  Young, BRCA positive individuals react to genetic testing 
and cope with information revealed as if cancer will be experienced in the near future 
(Hoskins & Warner-Lin, 2012).  These fears may push some young carriers to undergo 
surgical treatment well before the recommended timeframe.   
Young, BRCA positive individuals may seek risk management advice from their 
primary health care providers, surgeons, or gynecologists.  Health care providers are 
unlikely to be trained to handle the sensitive nature of these topics for this age group.  
Unlike many other mutation positive individuals, emerging adults’ surgical decisions 
cannot be made quickly.  This group needs support to assure that they have considered 
the complexities related to their decision and its potential ramifications over the life 
course (Werner-Lin et al., 2012). 
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BRCA1/2 positive emerging adults are unique in the sense that the traditional 
options given to individuals, such a surgical choices and reproductive planning, may not 
seem to apply at the time of genetic test result disclosure.  Reproductive issues and 
surgical options may be highly appropriate subjects for young carriers to learn of in a 
genetic counseling session, since they may not have not begun or completed their 
families (Kwong, & Chu, 2012; Ormondroyd et al., 2012).  The ability to carefully think 
ahead and plan for the future is a unique opportunity this group has, when compared to 
older BRCA1/2 carriers.  The sensitive and complex nature of the topics related to BRCA 
as well as the likelihood that they will have an impact on each individual’s life requires 
careful discussion with trained health care providers to navigate through possible issues 
(Ormondroyd et al., 2012).  Fear of developing cancer may lead some to undergo 
surgeries or surveillance while for others the waiting game may elicit ongoing anxiety. 
 Guidelines suggest that high-risk individuals could start screening at age 25 or at 
10 years prior to the earliest age of diagnosis in their family (Berliner et al., 2013; 
Trepanier et al., 2004).  Recommendations typically bypass this group.  It is 
recommended that annual mammograms and breast MRIs should begin at age 25.  
Clinical breast exams (CBE) should be done annually or bi-annually starting at age 25 
(Berliner et al., 2013). At the age of 30, women can elect to have CA-125 screening and 
transvaginal ultrasounds to screen for ovarian cancer, even though the utility has yet to be 
proven for ovarian cancer screening.  Chemoprevention may be considered.  Oral 
contraceptives have been known to decrease the risk of ovarian cancer up to 45-60% if 
used over a period of five years in high-risk women who have a history of ovarian cancer 
(Berliner et al., 2013).  Medications such as tamoxifen or other chemopreventive drugs 
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reduce the risk of developing breast cancer as well, reducing the risk for invasive breast 
cancer by about 44% for women 49 and younger (Fisher et al. 1998).   
Two main risk-reducing surgical options are available for women with a BRCA1/2 
gene mutation.  Risk reducing bilateral mastectomy would reduce the risk of breast 
cancer by at least 90%.  There is no standard age for which this is recommended.  A risk-
reducing bilateral salpingo-oophorectomy (BSO) would reduce the risk for ovarian 
cancer by 80-96% and reduces the risk of breast cancer by up to 50% in women who 
have not yet gone through menopause.  Surgery recommendations are for BRCA1/2 
positive women ages 35 to 40 (Berliner et al., 2013).  
This study built on a growing collection of literature on emerging adults with 
BRCA1/2 mutations (Hoskins & Werner-Lin, 2012; Hoskins et al., 2014; Werner-Lin et 
al., 2012).  We aimed to reach a greater number of geographically diverse participants by 
offering the opportunity to complete an internet-based survey.  We gathered information 
from individuals who received their positive genetic test result by age 25 with the 
intension of making this information available as a resource for health care professionals.  
This information will enable providers to better understand the unique support and 
guidance needs of these very young BRCA1/2 carriers (Hoskins et al., 2014).      
We hypothesized individuals who obtained their positive genetic test result by age 
25 would be satisfied with their decision to undergo testing as well as with the choices 
they have made regarding surveillance and surgery.  Further study objectives are below.    
 Comparisons were made between participants under the age of 25 and participants age 
25 or older at the time of study but had their positive genetic test result by age 25:  
o We predicted participants under 25 will be less satisfied. 
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o We predicted participants under 25 would feel their timeline for life is more 
affected. 
 Life instability was analyzed (i.e. more residency changes/shorter relationships): 
o We predicted less satisfaction with undergoing genetic testing. 
o We predicted timeline for life and overall life plans would feel more affected.  
 We predicated finding numerous metaphors (comparing two unlike things).  
 We predicted participants would recommend seeing a genetic counselor. 
o We predicted more satisfaction with the decision undergo genetic testing. 
o We predicted timeline for life and overall life plans would feel less affected. 
2.3 Materials and Methods 
   2.3.1 Sample Selection Criteria. Participants recruited were BRCA1 and BRCA2 
mutation positive individuals who underwent genetic testing before age 25.  Criteria for 
selecting participants included (1) BRCA1 or BRCA2 mutation carriers, (2) over age 18 at 
the time of the study, (3) received their genetic test result before age 26, and (4) English 
speaking.  Participants could be of any age at the time of the study.  Participants not 
meeting criteria were excluded.  Unlike previous works (Hoskins & Werner-Lin, 2012; 
Werner-Lin, et at., 2012), we did not exclude participants who had received a cancer 
diagnosis.  While the study did invite male participation, the final participant pool 
included solely women.     
   2.3.2. Recruitment. Participants were recruited using convenience and purposive 
sampling.  Participant recruitment was open from September 30, 2013 to February 6, 
2014.  Recruitment proceeded via different forms of social media (Appendix A).  
Standardized recruitment announcement templates were designed to maintain the 
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consistency of the invitations for the participants (Appendix B).  Each message was 
tailored to fit the type of social media or online forum.  Templates contained an 
embedded link to the survey and contact information for the investigators.  
Recruitment proceeded via invitation posted on three FORCE message boards.  
Messages were posted on the Main Forum, the Young Previvors Forum, and the Research 
Opportunities Forum.  Further recruitment proceeded through Bright Pink via two tweets 
from their Twitter account.  Facebook groups and blogs related to BRCA aided 
participant recruitment by posting messages containing the survey link on their pages.  
Each Facebook group was contacted by direct message prior to the posting being made.  
   2.3.3. Survey Design. An online survey was constructed by the researcher.  A survey 
from a related, previous work was utilized to guide question creation (Werner-Lin et al., 
2012).  The final survey was reviewed and approved by the thesis advisory team.   The 
study was hosted on SurveyMonkey.com.  It consisted of forty questions designed to 
assess both participants’ satisfaction with their decision to undergo genetic testing and 
participants’ feelings about life choices made (Appendix C).  The 40-question survey 
included: 
 Yes/no with corresponding open-ended prompt (15 questions) 
 Demographics and participant characteristics (11 questions) 
 Open-ended (5 questions) 
 Satisfaction with Decision Scale (SWDS) (6 questions) 
 Likert-scale style questions (2 questions) 
 Yes/no to follow-up call with link to a support resource (1 question) 
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The 15 yes/no questions each had a quantitative and a qualitative component, 
which was designed to assess how a positive genetic test result affected decision-making 
and life choices made.  Among these yes/no questions were three questions regarding life 
planning.  The life planning choice questions included asking participants if they had a 
medical management plan in place, if they had received genetic counseling, if they had 
been informed about family planning or reproductive options.  The Likert scale-type 
questions were designed to assess the degree of worry over life events and the helpfulness 
of specific types of healthcare providers.  The life events included finding a job, finding a 
place to live, completing school or duties at work, finding a partner or getting married, 
having children or family planning, and reducing your risk for cancer via surgery, 
treatment, etc.  Open-ended questions were designed to assess participant perception of 
cancer risk or knowledge gained through BRCA-related experiences.  Participants were 
asked to share advice for future BRCA1/2 positive people under age 25.  
The demographic and participant characteristic questions were used to obtain data 
on current age, age at time of genetic testing, sex, race/ethnicity, personal income, and 
highest educational level.  Individuals were asked if they have a BRCA1 or BRCA2 gene 
mutation.  Current relationship length and the number of residence changes in the past 
eight years were asked to assess life stability, since these two factors change frequently 
for many emerging adults (Arnett, 2000).  Participants were also asked if they had been 
pregnant and the number of sons or daughters that they have.  In the final question of the 
survey, participants were asked if they would be willing to receive a follow-up phone 
interview if needed.  Participants who responded yes were asked to leave their contact 
information.  Participants were provided the link to the “find a genetic counselor” feature 
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on the National Society of Genetic Counselors (NSGC) website at the in case they felt 
distressed or in need of additional support.  No follow-up phone calls were made.   
  To determine participant satisfaction with undergoing genetic testing, a previously 
developed survey tool was used.  It was designed to gauge satisfaction with health care 
decisions (Holmes-Rovner et al., 1996).  The Satisfaction With Decision Scale (SWDS) 
is positively correlated with decision-making confidence and has a proven reliability of 
86%.  It had a Cronbach’s Alpha score of 0.86. The aim was to see if participants were 
satisfied with their decision to undergo BRCA1/2 genetic testing at a young age.  
  The SWDS questions were reviewed and analyzed via a Cronbach’s Alpha test, 
like Holmes-Rovner et al. (1996).  It was expected to be reliable since the SWDS had 
been proven reliable previously in a study of BRCA1/2 mutation carriers who underwent 
genetic testing after using a computer-based decision aid (Green et al., 2004).  The 
SWDS also is a concise way to evaluate participant satisfaction with undergoing genetic 
testing.  We desired to minimize the potential for loss of participants due to the length of 
the survey overall (Holmes-Rovner et al., 1996; Kasparian & Wakefield, 2007). This 
research study was approved by the Institutional Review Board, Office of Research 
Compliance, of the University of South Carolina, Columbia, SC. 
   2.3.4. Data Collection.  Participants were targeted via a variety of social media venues.  
Participants who clicked on the embedded survey link, which was found in each of the 
invitation to participate templates, were brought to the first page of the study.  The first 
page consisted of a consent document that explained the goals of the study, potential 
benefits and risk to participants, and the contact information for the primary researcher as 
well as the director of thesis.  Following the consent document, the survey consisted of 
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eight pages of questions.  Once data collection was complete, all data was downloaded as 
excel files and stored on a password-protected computer.       
   2.3.5. Data Analysis.  The primary researcher met with a statistician to develop an 
overall plan for quantitative data analysis.  SPSS predictive analysis software, version 
22.0, was used to analyze of the quantitative data.  Chi-square test with Fisher’s exact test 
was used to determine correlations and infer independence among categorical data.  The 
categorical data included participants responses to questions such as educational level 
reached.  Spearman’s Rho was employed to determine correlations and infer 
independence for the ordinal data.  The ordinal data included participant responses to 
questions such as the length of time they have been with their current partner and their 
number of residency changes.  Percentages were used to review and depict what percent 
of young mutation carriers were concerned about specific life events, such as finding a 
job or reducing their cancer risk.  Cronbach’s alpha was preformed to confirm the 
validity of the SWDS tool.  
Data from the open-ended questions was analyzed using Content Analysis.  
Participant responses were printed onto paper, cut into strips, and color-coded based on 
the content of each participant’s response by the researcher.  Recurring themes and trends 
in the overall data were obtained.  Frequency counts based on the number of times a 
particular theme was mentioned in a participant response were obtained.  Tables and 
figures were developed to visually display key findings and participant demographics.   
   2.3.6. Benefits and Risks of Study.  This study provided no direct benefits or risks to 
participants.  Young, BRCA positive individuals may have benefited by having the 
opportunity to express the knowledge and experience gained through past experiences 
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(Birch & Miller, 2010).  Enabling young, BRCA positive women to share and describe 
their experiences has potential therapeutic benefits, especially if they felt as though they 
were helping others (Ziebland et al., 2013).  The risks to participants were minimal.  
When thinking about their own past experiences, participants may have felt sad or upset 
by their circumstances, decisions, or changes in life. 
2.4 Results 
   2.4.1. Participants.  Responses were gathered from 72 participants, but 63 met study 
criteria (N = 63) (Figure 2.1).  At the time of survey, about 40% of participants were 
under age 25 while about 60% were 25 or older (Figure 2.2). 
 
 
 
 
 
 
Figure 2.1. Criteria for study participation.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Participant ages at the time of study. 
All Study 
Participants 
(n = 72) 
Particpants Meeting Criteria  
Participants who had their 
BRCA1 and BRCA2 test  
result by age 25 
 (N = 63) 
~ 40%  
Under Age 25 
~ 60%  
Age 25 or Over 
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Participant ages are shown in Table 2.1. Participants’ average age at the time of 
results disclosure was 22, while the most commonly reported age was 24.  The average 
age at the time of survey was 26, but most participants were age 24.  Most participants 
were White/Caucasian (87%), held a Bachelor’s degree (32%), had an average personal 
income between $30,001 and $50,000 (37%), and had no children (67%).  Most often, 
participants changed their place of residency three times in the past eight years and had 
been with their spouse or partner an average of three years.   
 We met our goal of exceeding 60 participants; however, our sample size 
lacked diversity in terms of sex, race or ethnicity, highest educational level, and income.  
All participants were women, a large majority were White or Caucasian (87%), over 60% 
had achieved a Bachelor’s degree or beyond and had personal incomes of $30,0001 to 
$50,000 or greater.  Geographically, our study succeeded in reaching out to participants 
beyond the United States.  Facebook groups utilized in obtaining research subjects 
included at least three groups based out of Canada or the United Kingdom.  Among 
participant responses, at least six participant responses acknowledged that they were 
located or had received care and services at countries outside of the United States.     
   2.4.2. Satisfaction.  The reliability of the six question Satisfaction with Decision Scale 
(SWDS) as a single composite score for overall satisfaction with the decision to have 
genetic testing was determined using a Cronbach’s alpha test (α = 0.835).  Alpha scores 
were above 0.70 indicating that the SWDS showed good internal reliability and was 
effective at assessing participants’ satisfaction with the decision to undergo genetic 
testing.  Table 2.2 lists the six questions that make up the SWDS.  
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Table 2.1. Participant characteristics and demographics. 
 
  Average Range  Mode 
Age genetic test result received (years) 22 16-25 24 
Age at time of survey (years) 26 19-40 24 
Children (n = 35)    
   Total 0.7 0-4 0 
   Number of daughters 0.3 0-2 0 
   Number of sons 0.3 0-2 0 
Residency changes (last 8 years) (n = 47) 3 0-8 3 
Years with current spouse/partner (n = 42) 5 0-15 3 
 N %  
Sex    
   Female  100%  
Age at time of survey, by age group     
   Under 25 19 40%  
   25 and Over 28 60%  
Gene with mutation identified (n = 63)     
   BRCA 1  37 59%  
   BRCA2  25 40%  
   Unsure  1 1%  
Race/ethnicity (n = 47)    
   American Indian or Alaskan Native 1 2%  
   Hispanic American 1 2%  
   White/Caucasian  41 87%  
   Other 4 9%  
Education (n = 47)    
   Finished high school or GED 3 6%  
   Some college education 9 19%  
   Associate's degree 7 15%  
   Bachelor's degree 15 32%  
   College beyond a bachelor's degree 13 28%  
Personal Income (n = 43)    
    Less than $12,000 8 19%  
   $12,0001 to $30,000 4 9%  
   $30,001 to $50,000 16 37%  
   $50,001 to $100,000 14 33%  
   More than $100,000 1 2%  
Pregnancy (n = 46)    
   No 31 67%  
   Yes 14 30%  
   N/A 1 3%  
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Table 2.2.  SWDS questions and response options. 
 
The Satisfaction with Decision Scale: Decision to have genetic testing  
1. I am satisfied that I was adequately informed about the issues important to my decision.  
2. The decision I made was the best decision possible for me personally.  
3. I am satisfied that my decision was consistent with my personal values. 
4. I successfully carried out the decision I made. 
5. I am satisfied that this was my decision to make. 
6. I am satisfied with my decision.  
Response options: 
1- strongly disagree, 2- disagree, 3- neither agree nor disagree, 4- agree, 5- strongly agree 
 
Average scores for the SWDS were determined using an ANOVA test, and then 
compared to participant ages at the time of testing.  An ANOVA test was used for the two 
age categories, to see if there was a difference in testing satisfaction. Results are shown in 
Table 2.3.  Although participants under the age of 25 had slightly higher satisfaction with 
their decision to undergo genetic testing than the 25 or older age group, this difference 
was not statistically significant.      
Table 2.3.  SWDS and age at time of study. 
  N Average Score Standard Deviation  
Overall  63 4.7 0.66 
Age group     
   Under 25 19 4.8 0.28 
    25 and over 28 4.6 0.82 
 
The SWDS was compared to the two participant age groups at the time of study, 
education level, and personal income to see if relationships between participant 
demographics and satisfaction were associated with the decision to undergo genetic 
testing.  The SWDS was also compared to participants’ life planning.  Life planning 
choices included yes or no responses about their BRCA status affecting their timeline for 
life or overall life plan.  It also included if they had a medical management plan in place, 
if they had met with a genetic counselor, or if they had been informed about family 
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planning or reproductive options.  These comparisons were performed using ANOVA 
test.  The results are shown in Table 2.4.  
To assess participant satisfaction with the decision to undergo genetic testing, 
ANOVA was used to compare whether or not a participant thought their positive 
BRCA1/2 mutation status had an effect their overall life plan.  This was statistically 
significant (p = 0.04).  Therefore, participants who report life plans were impacted by 
their BRCA1/2 positive result were more likely to report an effect on their satisfaction 
with undergoing genetic testing.  The most satisfied participants still reported that 
knowing that they were BRCA1/2 positive impacted their overall life plans.  Therefore, it 
seemed that regardless of the outcome BRCA had on participants’ lives, they still were 
still pleased with their decisions to have genetic testing.     
Table 2.4.  SWDS vs. participant demographics and life planning choices. 
 df   
  between-groups within-groups F p 
Age at time of study, by age group 1 44 1.04 0.32 
Education 4 38 1.24 0.31 
Personal income 4 44 0.16 0.70 
Timeline for life 1 51 1.5 0.23 
Overall life plan 1 51 4.55 0.04* 
Medical management plan 1 51 0.61 0.69 
Genetic counseling 1 51 0.14 0.71 
Family planning or reproductive options 1 50 0.08 0.78 
 
2.4.3. Quantitative Data Regarding BRCA-Related Experiences and Choices. 
Participants answered 15 yes or no questions about experiences and choices they have 
made related to BRCA (see Table 2.5).  Nearly half of participants reported that their 
overall life plans or goals they desired to achieve were affected by testing positive for the 
BRCA1/2 gene mutation (57%).  Nearly three-quarters of participants responded that 
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testing positive for a BRCA1/2 gene mutation caused them to feel as though the speed of 
their timeline for life events was altered (71%).  A majority of participants had not 
received a cancer diagnosis (95%), were undergoing breast screening (77%) with normal 
outcomes (65%), had undergone some form of breast surgery (58%), and had not 
undergone a surgery related to the ovaries or female reproductive organs (85%).  Only 
2% of participants had utilized chemopreventive drugs. A majority had a medical 
management plan in place (88%) and all had considered risk-reducing surgeries (100%).  
Most received genetic counseling (84%).  A majority of participants had not been 
introduced to reproductive or family planning options, such as PGD (preimplantation 
genetic diagnosis) with IVF (in-vitro fertilization), adoption, or surrogacy (52%).  
Education level was compared to the three life planning choice questions and age 
at the time of the study (See Table 2.6).  A significant association was found between 
participant education and if they had received genetic counseling, χ2(4, N = 51) = 11.16, 
p = 0.03.  Participants were more likely to have had genetic counseling if they had 
reached a higher level in their education.  
Regardless of age, most participants reported a mild level of worry about reducing 
their risk for cancer.  More participants under the age of 25 selected the high level of 
worry option (16%) when compared to those age 25 or older (6%) regarding reducing 
their risk for cancer.  The under 25 group also tended to have more worry regarding 
completing school or duties at work, with 26% selecting the high concern option.  Only 
10% of the women in the 25 and older group expressed high worry over school or work 
duty completion.  A majority of women under age 25 expressed a low level of worry with 
finding a partner or getting married (32%) and having children or family planning (37%), 
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while most of those age 25 or older said they were not worried (71% and 45%, 
respectively) and think about these rarely.  A majority of women who participated in this 
study expressed none to low or mild worry levels regarding these life event categories.   
Table 2.5.  Participants’ experiences and choices related to BRCA. 
Question Yes No Other 
Q3: Have you ever been diagnosed with cancer? (n=59) 5% 95%  
 
Q4: Have you ever had a mammogram, MRI, breast ultrasound, or 
breast imaging study? (n=60) 
77% 23%  
 
Q5: Have you ever had an ABNORMAL mammogram, MRI, breast 
ultrasound, or breast imaging study? (n=60) 
35% 65%  
 
Q6: Have you ever had a normal or abnormal tissue biopsy? (n=59) 20% 80%  
 
Q7: Have you ever had breast surgery? (lumpectomy, mastectomy, 
etc.) (n=59) 
58% 31% 11% Planned but not 
taken place 
Q8: Have you ever had a surgery related to the ovaries or other 
female reproductive organs? (Hysterectomy, tubal ligation, 
conization, bilateral salpingo oophorectomy, etc.) (n=59) 
14% 85% 1% N/A 
Q10: Have you ever considered having a surgery to reduce your risk 
of cancer? (n=59) 
95% 5%   
Q11: Have you ever used any chemopreventive drugs? (Ex: 
Tamoxifen, Evista, etc.) (n=57) 
2% 96% 2% N/A 
Q13: Do you think testing positive for a gene mutation affected the 
timeline for your life? For example, do you feel like you need to 
speed up or slow down some of your plans for the future? (n=51) 
71% 29%  
 
Q14: Do you think testing positive for a gene mutation affected your 
overall life plan? (Ex: desire to have children, marriage, etc?) (n=51) 
34% 57%  
 
Q15: Do you currently have a plan in place for your future health 
care, related to your positive BRCA genetic testing result? (Ex: have 
a medical management plan including starting mammograms at an 
early age and....) (n=51) 
88% 12%  
 
Q18: Have you ever received genetic counseling? (n=49) 84% 16%  
 
Q19: Have you ever considered a risk-reducing surgery? (n=49) 100% 0%  
 
Q20: Have you been introduced to different types of family planning 
or reproductive options based on the mutation in your BRCA gene? 
Examples may include: PGD (preimplantation genetic diagnosis) 
with IVF, adoption, surrogacy, etc. (n=52) 
48% 52%  
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Table 2.6. Participant level of concern or worry regarding life events (%). 
Percentage of Participants at Each Level of Concern or Worry (%) 
  
Think about 
rarely: 
Think about 
once/twice a 
month: 
Think about a 
few days a 
week: 
Think about 
daily: 
Think 
about 
Constantly: 
  None Low Mild Moderate High 
58% 5% 11% 16% 11% Finding a job 
65% 6% 19% 0% 10% 
58% 26% 5% 11% 0% Finding a place to live 
77% 10% 3% 10% 0% 
32% 5% 16% 21% 26% Completing school or 
duties at work 
42% 19% 19% 10% 10% 
26% 32% 16% 16% 11% Finding a partner or 
getting married 
71% 13% 6% 3% 6% 
11% 37% 32% 11% 11% Having children or 
family planning 
45% 32% 16% 6% 0% 
5% 26% 42% 11% 16% Reducing your risk for cancer (surgeries, 
treatment, etc.) 
23% 19% 29% 23% 6% 
Key: Participant age at time of study, by group: Under 25 (n=19) 25 and over (n=31) 
  
 Participants were asked to rate how helpful or unhelpful specific types of 
healthcare providers were at providing support and guidance.  They were asked to say if 
they found them very helpful, somewhat helpful, neither helpful or unhelpful, somewhat 
unhelpful, or very unhelpful (shown in figure 2.3).  
The number of years participants were with their partners and the number of 
residency changes participants had in the past eight years were asked to gauge life 
stability.  These questions were compared to whether or not participants felt that their 
positive BRCA1/2 mutation status affected their timeline for life or their overall life plans.  
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These questions were compared using an ANOVA test.  There was no significant effect 
between years with partner and timeline for life, F(1, 32) = 0.89, p = 0.35.  There was no 
significant difference between the number of years with partner and overall life plan, F(1, 
32) = 0.46, p = 0.50.   There was no significant difference between number of residency 
changes an timeline for life, F(1, 34) = 0.16, p = 0.70.  No significant difference between 
number of residency changes and overall life plan was found, F(1, 34) = 0.01, p = 0.92.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.  Healthcare services rated by their provision of support and guidance.  
2.4.4. Themes. 
Life experiences and outlook.  Participants reported details about experiences 
they have had with family members or healthcare providers.  Participants wrote responses 
regarding their outlook on life after testing positive for a BRCA1/2 gene mutation (see 
Table 2.8), which were analyzed for common themes.  Most often, participants had an 
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accurate perception of their cancer risk (n = 22) while many others either overestimated 
their risk (n = 16) or quoted the correct risk figures, yet said they thought their risk was 
higher based on their family history (n = 14).  Most also noted seeing family members 
fight against caner (n = 38).  A main theme was that knowledge of their BRCA1/2 had a 
positive impact and they were hopeful for the future.  Participants wrote that it as a 
chance to seize opportunity (n = 14) or that it would not alter plans (n = 9).    
Positive Outlook. 
- I still had children, got married, lived it up in my early 20s, went to 
college.  BRCA positive results did not slow my life down.  They gave me 
the tools I needed to ensure my life would go on.   
BRCA was a Positive that Led to a Career Change.   
- Testing positive and confronting my risk via preventative mastectomy 
changed my perspective on life drastically.  While I always valued health, 
being a good person, and contributing to the world in a meaningful way, 
prior to my surgery I wasn’t actively pursuing these priorities.  My career 
plans have changed – rather than staying in the field of marketing I am 
pursuing graduate school for epidemiology.  I pursue goals because I 
believe they are meaningful and will fulfill me, rather than for the 
appearance of success.  As much of a burden as testing positive is, it is 
also a blessing in disguise if you let it.   
- Made sense that I would be [positive], I can help so many with what I 
have access to and what I know as a nurse, and personal experience now 
with surgery, and passion fueled by loss of life in family members.  
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Table 2.8.  Life experiences and outlook. 
Life experiences and outlook (n = 168) n 
Family history shaping perception of risk 60 
Accurate perception of cancer risk 22 
Overestimating cancer risk 16 
Quote accurate numbers, but believe it is higher because of family history 14 
Underestimating cancer risk 3 
Overestimate risk before to prophylactic surgery, now underestimate risk  2 
Metaphors as a way to think about cancer risk 2 
Quote accurate numbers, but believe it is higher because had cancer 1 
Witnessed family members fight against cancer 38 
Chance to seize opportunities 14 
Positive impact on life plan / led to specific career path 4 
Eat healthier and spend more time with family 4 
Always felt there was no time to waste because of family history 4 
Travel more 2 
Conflict about what is best for young carriers 12 
Tried to talk out of having prophylactic surgery   3 
Pushed to have a family before they felt ready 2 
Tried to talk participant into having reconstruction 1 
Did not want to work around college class schedule  1 
Physician disagreement over hormone replacement therapy use   1 
Difficulty providing appropriate care for young carriers 9 
Doctor uninformed about BRCA and not knowing how to provide care 4 
Genetic counselors with recommendations not fitting for someone so young 3 
BRCA will not alter plans 9 
Altered self-image 6 
Due to mastectomy 4 
Due to screening or biopsy 2 
BRCA as a death sentence  5 
Is not a death sentence 4 
Felt like a death sentence  1 
Denial about cancer risk 5 
Recent or impending loss of a family member as a reason for denial 4 
Did not expect to be BRCA positive 1 
Feelings of hopelessness 3 
Concerns involving insurance  3 
Planned for a career with good insurance because of BRCA 2 
Concerns over future insurance coverage, even though protected by law now 1 
Knowing your mutation status as a blessing 2 
Angelina Jolie’s decision as eye opening 2 
 
Overestimation of cancer risk.   
One participant wrote: I believe my risk would be approaching 100% - 
every woman on the BRCA1+ side of the family has battled cancer more 
than once, my aunt has had 8 diagnoses of cancer in the last 30 years.  I 
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am the first to have engaged in risky behaviors such as smoking and heavy 
alcohol consumption.  Statically I know that my breast/ovarian risk is 
quite low now, however with a 53% chance of surviving to the age of 70, I 
have decided to approach my carrier status as absolute, otherwise I fear 
gambling with statistics might cost me my livelihood or my life. 
Another wrote, “95% because both my grandmothers had breast cancer and my 
mother had both breast and ovarian cancer and now that I know I have a BRCA1 gene 
mutation I know my risk is vary high.”  A third explained, “I had a 98% chance by age 
30, it wasn’t an option to not be preventative [and undergo mastectomy].”  Another 
participant used a metaphor to explain her risk: “Before surgery, it was 55-85% [for 
breast cancer] …for ovarian 10-60%, ‘average risk of 31%’. The way I see it, even if my 
risk for breast cancer was ‘only’ 45 or 55%, I made the right decision for me in having 
prophylactic surgery.  If you knew that ‘only’ 1 out of 2 vehicles sold by a particular 
manufacturer exploded spontaneously, would you still buy the car?” 
Affected Self-Image.    
- [I had] double-mastectomy with skin and nipple-sparing reconstruction.  
The months leading up to the surgery were the worst part emotionally.  
The anticipation and emotional preparation for losing a part of your body, 
particularly a part so close tied to your womanhood, is extremely difficult.  
I struggled with the fact that I wouldn’t be able to feel my breasts 
anymore, that I wouldn’t be able to breast-feed, and that I had no 
guarantee I would ever look “normal” again.  Recovery was difficult, but 
manageable with pain medication.  The hardest part for me was giving up 
38 
my mobility (not being able to use my arms, drive, exercise – even if I 
wasn’t in pain) until my drains were removed… The expansion process 
brought on insecurities – did my boyfriend still find me attractive?  Did 
people get weirded out when I hugged them and my boobs felt hard as 
rocks?  I pushed through… The overall result has been fantastic. 
Cosmetically?  My boobs rock.  Better than my natural ones ever were.  I 
had a great doctor! 
- I had a normal MRI guided core biopsy.  …This experience was 
considerably more trying then expected… I was surprised how negatively 
my self-image was affected by the procedure, the busing, the pain in my 
breast.  It also brought forward thoughts and concerns of how I will be 
able to cope if I choose to go forward with surgeries in the future.  I found 
these concerns in addition to the stress of the procedure to be more 
stressful than any worry about potential results. 
Denial. 
- Anyone who asked, I told them I was 95% sure I did not carry the gene, 
so I had no concern about being told [my result] over the phone.  I got the 
call at home while my daughter was napping, and it was just me.  I was 
devastated.  I could not get off the phone fast enough because I just 
wanted to sit and cry by myself.  After I calmed down, I called my 
husband at work and told him, and then cried all over again. …It was a 
major shock to me.       
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Hopelessness.  Two participants wrote about hopelessness in relation to finding 
out their test result.  One replied, “Mixed [thoughts on prophylactic surgeries].  I suspect 
I will do them and then die of pancreatic cancer at 60.  So it feels a bit useless.  Then 
again better to die at 60 than at 35 I guess.”  Anther wrote, “There was a certain amount 
of hopelessness that came along with my test results… it paralyzed me for a long time.”     
Impact of Angelina Jolie’s Decision.  
- I eventually came to the tentative decision that a prophylactic 
mastectomy was something I’d be interested in doing as soon as I moved 
back to the states.  And then Angelina Jolie wrote that article about her 
own decisions and suddenly all I could focus on were the negative 
comments.  People calling her surgery ‘self mutilation’ and an 
overreaction.  I started to back-track a little.  Was the decision I had come 
to (independent of her article) short-sided?  Was I only doing it out of 
panic?  I threw myself back into researching the same things I had before, 
but this time I had the added bonus of doing it AFTER everyone had read 
Jolie’s article and suddenly there was this wealth of information and 
firsthand stories that I hadn’t seen before.  It was much easier for me to 
find stories and blogs of girls MY AGE who has gone through the same 
surgery and explicitly stated how much they didn’t regret the decision. 
- I received my results in a meeting with my genetic counselor.  Honestly, 
at the time I had no idea what it meant at that time and couldn’t 
understand why the counselor seemed so serious.  I’d just lost my dad, so I 
guess it didn’t really sink in.  …I really had no idea of the gravity of the 
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situation until mid-2013 when Angelina Jolie announced her PBM – I 
thought wow, that’s serious.  So even though it was in the back of my 
mind for seven years or so, and I suffered a lot of fear from the uncertainty 
and my own ignorance, I only began to take it seriously after being 
catapulted into the BRCA world by a celebrity.  Even though I have seen 
all the women on my dad’s side suffer from HBOC syndrome and all but 2 
of the have died because of it. 
Insurance. 
- I decided to this surgery NOW because I have found myself in a very 
specific position: I had just moved back to the states and was unemployed; 
I was under the age of 26 and could join my parents’ health insurance 
plan; and would be living in a house with people who had already hone 
through the aftercare process with my mom & would know what to 
expect.  Delaying my job search for a year (my biggest hang up) seemed a 
lot more logical to me under those circumstances. 
- I had different priorities in my early 20s even before testing because of 
my family history, e.g. having a job that provided health insurance.  
Obamacare would have changed that for me if I was younger because I 
could have stayed on my parents’ plan. 
Screening. Participants mentioned topics related to screening 128 times (n = 128).  
Main themes and the number of times participants reported specific details about 
screening are shown in Table 2.9. 
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Unfavorable Screening. For one, “It was really uncomfortable because I had 
dense breast tissues since I was young and hadn’t had any kids yet.” Another reported, 
“The mammogram was awful.  The lady kept squishing them even after I said I couldn’t 
take it anymore.  The ‘pads’ were of no help. The ultrasound was completely okay.  It felt 
like a massage made specifically for my boobies.”   
Others wrote, “I have not enjoyed any of them [surveillance].  I find it brings me 
down and reminds me of being ill when I’m not” and “Anxiety could be the best way to 
describe my experience to all the tests I went through.  I was constantly worried they 
were going to find something and I would have to go through surgery, chemo, and 
radiation like my mom.” 
- It was a very stressful experience to even consider that I may have 
cancer.  The needle biopsy itself was invasive and painful.  In fact, this 
was probably the most traumatic experience I have had in dealing with my 
BRCA2 mutation (and I underwent a double mastectomy at age 22!). 
Surgical Decisions.  Responses were evaluated for themes using Content 
Analysis.  The number of times participants made comments related to surgical decisions 
were counted and summarized in Table 2.7.  Most participants mentioned surgical 
choices they either have made or will make in the future (n = 100).  The most commonly 
mentioned surgery was prophylactic bilateral mastectomy (n = 40).  Other trends in the 
data included waiting until after having a family (n = 29), having reconstruction (n = 18), 
having a oophrectomy in the future (n = 18), and being shaped by watching other family 
members experience cancer (n = 20).  Fourteen people had misconceptions about surgical 
choices, with most noting either that they had or hoped to have a hysterectomy (n = 11).  
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Table 2.7.  Surgical choices and decisions made.  
Surgical Decisions (n = 234) n 
Surgery choices made or will make 100 
Mentioned that they had prophylactic bilateral mastectomy (ages noted: 21, 22, 25, 28, 37) 40 
Nipple sparing 2 
Bilateral mastectomy (following unilateral cancer diagnosis) 2 
Reconstruction  18 
Expanders then implants 2 
Expanders, implants, and nipple reconstruction  2 
Direct to implants (age 28) 2 
Tissue expanders then saline implants (age 28) 1 
Silicone implants (age 29) 1 
Will have prophylactic bilateral Salpingo oopherectomy and/or hysterectomy                      
(Ages: after 30, max 35, around 35, at 38, around 38, at 38, by 40, at 40, or after 45) 
18 
Will have prophylactic bilateral mastectomy (by 30, at 30, around 35-40, or before 40)  12 
Non-nipple or skin sparing  2 
DEIP flap reconstruction (age 27) 2 
Had bilateral Salpingo oopherectomy and/or hysterectomy (ages: 26, 27, 29, and 38) 9 
Davinci hysterectomy  1 
No reconstruction  1 
Surgery after children 29 
Already had / plan to have mastectomy, wait for oopherectomy 23 
Wait for both mastectomy and oopherectomy  6 
Desire to breastfeed children  3 
Surgery is "the best option" 22 
It was worth it 4 
I am young so recovery will be easier and faster  3 
Best option because no longer wanted to live life waiting for cancer  3 
The only option for me personally  2 
Family history shaping surgical choices  20 
Surgery because witnessed family members fight with cancer 11 
Do not want to children to have to watch me fight cancer 5 
Mastectomy and later oopherectomy because family members have chosen this 4 
Surgery "to prevent cancer" 16 
Misconceptions about surgeries warranted because of a BRCA1/2 mutation 14 
Noted hysterectomy or removal of uterus 11 
Only fallopian tube removal 1 
Oopherectomy not an option until after 45 1 
Noted cervical dysplasia and abnormal pap smears as motivation to undergo surgery 1 
Bilateral mastectomy to alleviate worry 13 
Set mind at ease / freedom from stress    8 
Reduce stress caused by surveillance and the potential to find cancer  5 
Unforeseen issues with surgery plans 6 
Surgical course was more painful and complicated than expected 4 
Skin necrosis and low blood flow following prophylactic bilateral mastectomy 3 
Problems with infection due to the skin not healing 2 
Complications with drains  1 
Lumpectomy led to more serious surgery due to positive nodes 1 
Frustration over length of time it took have surgeries completed    2 
Surgery to gain control over cancer 5 
Early menopause concerns 4 
Concern that bilateral mastectomy will affect sex life 3 
Insurance dictating timing of surgery  2 
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Mastectomy Prior to Childbearing. 
- I originally planned to have a bilateral mastectomy after having children.  
I finally came to a point where I was not willing to take the risk of getting 
pregnant and going without effective surveillance for 9 months, while my 
body went through hormonal changes.  
Family Experiences Impacting Surgical Choices.   
- At age 28, I had a [PBM].  My mom was only 29 when she was 
diagnosed with breast cancer, and she passed away at age 35 when I was 
only 6 years old.  I have two of my own young children and I vowed to do 
everything I could to avoid this happening to us.  It has been a long road, 
recovery hasn’t been easy, but I haven’t for a minute regretted it.   
- I had prophylactic bilateral mastectomy when I was 22.  I watched my 
mother get diagnosed and fight breast cancer twice and I was determined 
to stop cancer before it got me.  I wanted to prevent my children and 
family from going through what I went through watching my mom.   
Healthcare and Support.  Participants mentioned topics related to healthcare or 
support 115 times (n = 115).  Main themes and the number of times participants reported 
specific details about healthcare support are shown in Table 2.10.  
Major themes among participant responses included participants feeling either 
supported by their health care providers (n = 61) or frustrated by them (n = 16).  Most 
participants recommended seeing a genetic counselor (n = 14).  Other women 
recommended finding other people who are also BRCA1 or BRCA2 positive (n = 10).  
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Table 2.9.  Screening plans and thoughts on the options available.  
Screening (n = 128 ) n 
Screening protocol in place 92 
Yearly MRIs 12 
Every six months, CA-125 and transvaginal ultrasound 11 
Breast ultrasound, mammogram, and MRI (alternating) 11 
Every six months mammogram or MRI (alternating)  9 
Breast ultrasound and MRI (alternating)  8 
Yearly Mammograms (starting at ages 21, 35 30, or after testing positive) 6 
Yearly  5 
Birth control as a way to reduce the risk for ovarian cancer 5 
Undergoing screening for melanoma / seeing a dermatologist  4 
Concerns about pancreatic cancer because of family history   4 
Biannual breast MRI (post mastectomy)  4 
Yearly mammograms and MRIs.  (start at age 21) 3 
Yearly mammograms and breast ultrasounds 3 
Yearly CA-125 3 
UK has no ovarian cancer screening options 2 
Biannual CA-125 1 
Every three months CA-125 / every six months pelvic ultrasound 1 
Surveillance causing anxiety and stress 16 
Toll on mental state 5 
Stress over length of time an MRI takes 4 
MRI is nerve-racking 2 
Anxiety waiting for results after screening 2 
Surveillance as frightening because of family experiences with cancer 1 
Misconceptions about screening warranted because of a BRCA1/2 mutation 7 
Pap smears as screening 4 
Concerns for cervical cancer screening because in family history 2 
Need for colonoscopy 1 
Mammogram as painful or uncomfortable 4 
Dense breasts 2 
Large breasts 1 
Core needle biopsies or fine needle aspirations were painful 3 
Rechecks are more of a hassle or inconvenience  2 
Frustration obtaining insurance coverage for screening because of age 2 
Surveillance causing no pain or stress 2 
 
Supportive and Beneficial Providers.  “I think all experiences have been positive 
thus far [with healthcare providers].  Everyone seems either very knowledgeable, or they 
defer to someone else who is better acquainted with BRCA.”    Another commented that, 
“Karen Brooks was amazing.  She fully explained everything.”  
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Table 2.10.  Healthcare and support related to being BRCA1/2 positive. 
Healthcare and Support (n = 115) n 
Providers made me feel supported through decision making 61 
Empowered and supported my decision  10 
Explained everything so I understood 9 
Listened to my questions and concerns 9 
Helpful  8 
Empathy and compassion 6 
Explained the science   4 
Continued support over time / calls to see how I am doing 4 
Phone number that I can call at any time  3 
Respectful of what I did/did not know and explained when necessary 2 
Persistence and will not give up trying to help  2 
Being open with discussions 2 
Made me feel in control over my medical decisions 1 
Treated me like an adult 1 
Feeling frustrated by healthcare providers 16 
Unsympathetic or unsupportive care providers 6 
Lack of BRCA knowledge 3 
Having to advocate for own care / no one taking initiative  2 
Lack of clarity about when surgeries can take place 2 
Getting appropriate care during recovery from surgery 1 
Not trying to find answers to questions asked 1 
Not remembering who you are after repeat visits 1 
Recommend seeing a genetic counselor  14 
Supportive 6 
Helpful and accurate information 4 
Recommend genetic counseling before result disclosure 4 
Recommend finding other young mutation carriers 10 
Become part of the sisterhood to find others like you 7 
You are never alone 3 
Only positive experiences related to BRCA and clinical care 8 
Genetic counselors provided no new information 6 
Reviewed all options with a physician prior to genetic counseling 2 
Already knew a lot about BRCA from family experience 2 
Would not recommend or was frustrated by genetic counseling 2 
 
Trouble Receiving Age-Appropriate Care from Providers.   
- One oncologist I saw recommended that I see a therapist, after I came to 
her office expressing concerns about changes in my body.  I think she used 
‘overreacting’ in the conversation, even though she knew my risk.  It was 
incredibly frustrating to see a doctor dismiss concerns, when so much of 
surveillance is about doing self-breast exams and being aware of your own 
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body.  Many oncologists deal with older women who already have breast 
cancer and really have no idea what it’s like to live with BRCA. 
- A sonographer I recently encountered made it clear that she did not agree 
with genetic testing or the use of surveillance techniques for BRCA+ 
carriers.  It was a very awkward 20 minutes where I was interrogated until 
she felt I had justified having an ultrasound. 
Trouble Receiving Age-Appropriate Care from Genetic Counselors.   
- It was basically useless.  …They had no clue how to talk to someone 
who wasn’t 40.  They guy spent a bunch of time explaining what kind of 
surgeon I needed to find to do my oopherectomy.  Obviously, you need to 
provide information about what kind of prevention to do down the line, 
but they gave me really almost no sense of what I should be doing at 24.  I 
wouldn’t recommend genetic counseling to anyone. 
- A second wrote: The only really bad experience I had was with a 
genetics counselor. He was condescending and really seemed to have no 
idea how to talk to me, or to formulate advice from someone in her mid-
twenties. 
Recommend Genetic Counseling.  Fourteen participants commented favorably on 
genetic counseling and mentioned that they would recommend it to others.  One wrote, 
“Just having them spending the time addressing your questions and concerns.  The most 
important thing is to GET TO COUNSELING!  This is a major decision mentally, 
emotionally, and physically and you need to be prepared."  For another, "The genetic 
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counselor provided me the most helpful information and guidance in terms of risk 
percentages, risk reduction methods, and a preventative plan of action."     
- Definitely recommend genetic counseling with someone who specializes 
in BRCA.  There is so much misinformation on there and judgment from 
people or medical professionals that aren’t really in the know.  It's super 
important to talk about your specific situation and not just go based off 
general guidelines.  There is no one size fits all when it comes to things 
like this. 
- It was refreshing to speak to someone who was both impartial without a 
personal stance (that she demonstrated in her professional capacity at 
least) and who did not require explanations but was able to provide them.  
The information she provided was helpful for follow up conversations that 
I had with my family physician regarding my screening and medical 
decisions. 
Genetic Counseling Provided no New Information.   
- I did receive genetic counseling prior to my BRCA test.  Because my 
mother had tested positive a few years before and I had done a ton of 
research.  I knew most of what the CGC shared with me.  None of it was 
truly new information but I think genetic counseling is immensely 
valuable for those who are not as aware of what it means to be BRCA 
positive.   
- I had known that I may have BRCA2 since I was ten years old and had 
grown up discussing the issue with my mom, who had had breast cancer 
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when she was 36.  As a result, I didn’t get any new information from 
genetic counseling. 
- [A Genetic counselor] wanted to refer me for counselling as she felt ‘I 
wasn’t coping with the death’ of my aunt (she dies from pancreatic cancer 
with suspected link to the BRCA1 gene).  My aunt had only died a month 
prior to this session and I felt (and still feel) that I was coping well and 
simply working my way through the grieving process.   
 Altered timeline for life.  Participants indicated that they felt a need to speed up 
(n = 40) or slow down (n = 6) their timeline for life events after learning that they carried 
a BRCA1/2 gene mutation (Figure 2.4).  Participants reported feeling like they had to 
speed up having children (n = 18) or finding a husband (n = 9).  
Life Timeline as Either Delayed or Rushed. One wrote, “It makes me fell like I 
need to get married sooner and find a partner who would not mind if I have to have my 
breasts and reproductive organs removed.” 
- Although I have been married for over four years, my husband and I 
have not immediate plans for children.  My physicians have been 
questioning if this is something we would want to consider more 
immediately because of how it may affect future options.  While I do not 
want this to be the reason behind our family planning, I have found it to be 
creating pressure to speed up our conversations and plans for the future.  
Simultaneously, as we do not feel that we wish to start a family at this 
point, I feel that the two feelings are creating tension.  
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Figure 2.4.  Participants’ BRCA1/2 status as pressure to speed up or slow down life. 
Delayed Timeline for Life. 
- Testing positive didn’t affect the timeline for my life, however, my 
cancer diagnosis did.  I had to defer my education to undergo treatments 
…children would have to wait a year after finishing chemotherapy to 
ensure the drugs are out of my body.  
 
Faster  
Timeline  
for Life 
(40) 
Childern  
(18) 
Had them faster (8) 
Faster so ovaries can be 
removed earlier (5) 
Feel a need to have them faster 
(5) 
Husband/Partner  
(9) 
Looked for serious partners 
only (2) 
Got married quicker (4) 
Felt the need to marry more 
quickly (3) 
Education  
(7) 
Altered educational path (4) 
Planning when to complete 
degree vs. when to have 
surgeries or children (2) 
Motivated to not delay 
pursuing life goals (1) and 
career (1) I thought it would at 
first, but it has not (2) 
Now a big consideration 
when planning life  
(4) 
Slower  
Timeline  
for Life 
 (6) 
Underwent bilateral 
mastectomy (2) 
Cancer diagnosis / delayed 
wedding and having children 
(1) 
Prophylactic / delayed job 
hunt and moving out of 
parent's home (1) 
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Different Pressure than Older BRCA Carriers Feel.   
- It has affected my life timeline in terms of being more aware of decisions 
I need to take…. as I am still very young, I don’t feel under pressure by 
the remaining time that I have. (As opposed to women I have met who are 
approaching 40, single, wanting to have children, but needing to remove 
their ovaries soon).  I hope I will not have to face these challenges.         
Views on Family Planning Options.  Participants mentioned or discussed family 
planning options seventy-three times (n = 73).  Participants were asked to describe what 
they know or their thoughts on in-Vitro Fertilization (IVF), Preimplantation Genetic 
Diagnosis (PGD), adoption, or surrogacy.  Participants were asked if they were pursing 
family planning yet or what they thought there future plans may look like (Figure 2.5).  
Major themes included families being informed of PGD and IVF but not wanting 
to use the technology (n = 17).  Others had been informed about PGD and IVF and would 
consider using it (n = 16).  Other participants considered or planed to adopting in the 
future (n = 13) or elected not to have children (n = 11).      
Desire to Have Children the Natural Way.  One wrote, “I still plan to get married 
and having children.  With the technology that has come out I can only hope my children 
have the options plus more if they were faced with the BRCA gene.”   
- I still want kids gene or no gene.  I feel like it’s not fair that I shouldn’t 
have kids or a family just because of the gene.  I am just like everyone else 
and there are tons of other people having kids with other genes and issues.  
This is just my something and it shouldn’t stop me from leading a 
fulfilling life.  
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Figure 2.5.  Participants’ opinions on family planning options.   
 
Family 
 Planning  
Options 
(n = 73) 
Informed of IVF/PGD:  
Would not use it 
(17) 
Prefer the natural way (11) 
Chilren the natural way: IVF and/or PGD 
conflicts with personal beliefs (3) 
High cost of PGD (2) 
PGD is unnecessary (1) 
Not ready to think about family 
planning at this stage in my life 
(9) 
Informed of IVF/PGD:  
Would consider using it 
(16) 
Currently consulting providers about 
family planning option (3) 
Would consider or plan to do in the future 
(9)  /  Plan to freeze eggs (2) 
High cost of PGD (2) 
Adoption 
(13) 
Would consider or plan to do in the future (9) 
Unable to have childern but want to add to 
family (1) 
Desire for children has not changed, but 
testing positive made adoption a more 
attractive option (3) 
No children 
(11) 
No desire to have children (4) 
Unsure, but likly will not have children so the 
mutation will not be passed on (7) 
Never informed (4) / Family is 
complete (3)  
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Would not use PGD.  “It is expensive… PGD seems vaguely morally dubious.”   
Another responded: I was advised of the option to use IVF to select 
embryos without the mutation.  This option goes a little too close to 
playing with the powers of procreation for me.  …I know about my 
mutation and can help my daughters and sons know if they have a 
mutation as well and lead long healthy productive lives just like I am.  I 
don’t see it as a death sentence and don’t see like living a life with a 
BRCA mutation would be unfair to them or to me. 
High Cost of IVF and/or PGD.  One replied, “If I am in a fortunate financial 
position, I will consider PDG.”  Another felt, “Pre-implantation for BRCA is silly, it is 
not a childhood affecting disorder, it’s preventable 100% if you follow guidelines and 
pay attention to your body.  The IVF and other options are very nice, expensive but 
interesting.”  A third wrote, “I considered PGD.  Then I discovered it costs 3-4 times as 
much as regular IVF.”       
Would Consider PDG. One explained that, “I have always wanted children.  This 
changes how I am going to go about making a family.” 
- I’ve thought about adoption ONLY because I don’t know if I can have 
kids.  Seeing as how I have Endometriosis and miscarried several times, 
not sure if my body can handle having my own kids.  Of course I’ll try 
IVF, but if that doesn’t work then I definitely want to adopt.  
- A negative [of undergoing genetic testing] is that I ill consider in-vitro 
fertilization and BRCA2 testing my embryos when I’m ready to have 
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children.  I never would’ve thought of reproduction so clinically before, 
especially since I wouldn’t exist if my parents had that option.      
Would Consider Adoption.  For felt that, for her, “Whether they are of my womb 
or adopted I will be there mother, there is no changing that.”   
- PGD and IVF were presented to my husband and I, but because of our 
values and beliefs we will not take part in any of those options.  Adoption 
is an option we have considered not only because of the positive BRCA1 
results, but also because I may not be able to conceive after receiving 
chemotherapy.  
- As far as the future of my family goes, I never had a strong desire to 
have children.  As a carrier of this gene [mutation], I have less of a desire 
to bear my own children.  It has made me think differently about the idea 
of adoption…or just having lots of awesome pets. 
- I have never been very interested in having children, but having this gene 
mutation that I could pass down to any offspring makes me not want to 
have children.  It almost makes me feel like it is my duty not to have 
children, excluding the possibility of that life experience.   
- When I first got my BRCA results, I wanted to have kids before age 30, 
because experts say it reduces BC [breast cancer] risk.  Now that I’ve had 
cancer, though, I’m not sure I want to have kids at all.  I have a 50% 
chance of passing on the on and I’m not sure I want to do that and risk a 
child of mine going through cancer like I did. 
 
54 
2.5 Discussion  
   2.5.1 Participants. 
Despite efforts to obtain a more diverse study sample in terms of sex, 
race/ethnicity, education and income, the participant demographics in this study were 
quite similar to the demographics achieved in related studies (Hoskins & Werner-Lin, 
2012; Werner-Lin et al., 2012).  Lack of variability in terms of race or ethnicity, despite 
efforts to reach out to race or ethnicity-specific BRCA Facebook groups, was not ideal 
yet not unexpected.  Typically, African Americans as well as other minority groups are 
hesitant to take part in research (Sherman, Miller, Shaw, Cavanagh & Sheinfield-Gorin, 
2014).  However, the study expanded to other countries outside of the United States and 
reached a large number of participants.  Therefore, one of the key aims to increase 
sample size was achieved.   
   2.5.2. Satisfaction.  We hypothesized that individuals who obtained their positive 
genetic test result by age 25 would be satisfied with their decision to undergo genetic 
testing, but somewhat less satisfied then those who were older than age 25 at the time of 
the study.  This was predicted since young mutation carriers are less familiar with making 
autonomous decisions (Arnett, 2000) and have less mental capacity to examine each facet 
and consequence of the decisions at hand (Ford et al., 1998; Steinberg, 2005).  We found 
that all participants, regardless of age, were highly satisfied with their decision to 
undergo genetic testing.  Thus, age did not have an effect on testing satisfaction as we 
anticipated. This was consistent with previous data collected (Klemp et al., 2005).  This 
trend could be due to the fact that knowing in advance enabled young BRCA1/2 mutation 
carriers time to plan for the future and develop an optimistic view for the future and 
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future research (Donnelly et al., 2013).  For a number of participants, knowing their 
BRCA1/2 mutation status did bring them optimism and hope for the future (n = 29) and 
enabled them to regain their sense of control over cancer (n =5). 
   2.5.3. Recommendations for care providers and genetic professionals.  While every 
patient will be different and guide the way their care is provided, based on the data we 
collected, there are five recommendations we propose to guide counseling for BRCA1/2 
carriers under the age of 25.  Care provision recommendations for young BRCA1/2 
carriers include the five Rs. 
 Right Reproductive Organs: Discuss which female reproductive organs are 
and are not at risk (i.e., NOT cervical cancer) 
 Risk Reducing Mastectomy: Primarily discuss prophylactic bilateral 
mastectomy, with less time devoted to discussing oopherectomy  
 Risk Figures: Discuss age-specific risk figures and how lifetime empiric 
cancer risk figures are accurate for them, and hopefully we will have even 
more mutation-specific numbers in future  
(i.e., most BRCA1/2 positive women have a significant cancer family 
history)   
 Reproductive Options: Cover possible reproductive options  
(Not all pregnancies are planned and basic knowledge can be important for 
future or financial planning) 
 Resource for Future: Be an educated future resource  
(Their needs and questions will change over time; be there to answer them.) 
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These guidelines could benefit any health care professionals who work with 
mutation carriers under age 25.  However, both data from this study (n = 23) and previous 
research (Hoskins et al., 2014; Ormondroyd et al., 2012) emphasize the need for trained 
genetics professionals, such as genetic counselors, who fully understand BRCA.  Similar 
to Hoskins et al., BRCA1/2 carriers under age 25 in this study placed value providers who 
made them feel empowered (n = 10), had clear explanations (n = 9), listened to their 
questions (n = 9), were empathic (n = 6), explained the science (n = 4), and treated them 
like adults (n = 1) (2014).  Participants expressed frustration when healthcare providers 
were unsupportive (n = 6) or lacked knowledge about BRCA (n = 3) and the surgery 
guidelines (n = 2).  These findings emphasized the need for better care and more 
appropriate referrals to genetic professionals for mutation positive emerging adults.   
While genetic professionals were reported to provide excellent guidance and care 
(n = 14), assuring that the care provided is relevant for this age group is critical and one 
of the bases for our recommendations presented.  The topic of relevant care for women 
under age 25 is two-fold.  First, our study identified a need for clear guidelines regarding 
screening and surgery.  Conflicts regarding the best care strategies for BRCA1/2 positive 
women under the age of 25 emerged from the data (n = 12).  This confirmed what 
previous researchers found  (Hoskins et al., 2014).  We found participants were using 
over 16 different types and combinations of screening strategies.  This lack of uniformity 
regarding a surveillance protocol again supports the idea that a set guideline is necessary 
in providing adequate care for those under age 25.   
Second, our study identified a need for a unique counseling and care strategy for 
young mutation carriers.  Participants wrote that providers were misinformed or 
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unfamiliar with BRCA (n = 4) and that genetic counselors specifically did not know what 
types of recommendations are fitting for such young carriers (n = 3).  This led to 
participant frustration with genetics professionals who provided them no new information 
related to BRCA (n = 6).  This data indicated that future steps are necessary to assure 
BRCA1/2 positive emerging adults are receiving care that is relevant at their young age.                  
Right Reproductive Organs.  The data showed that participants had many 
misconceptions regarding both surgeries and screening related to BRCA1/2.  This is 
consistent with previous literature (Patenaude et al., 2013).  Of primary concern were 
women discussing cervical cancer, which is a type of cancer unrelated to BRCA1/2 gene 
mutations (Clark & Domchek, 2011).  Participants expressed concerns about cervical 
cancer in their family history (n = 2) or personal history (n = 1) and that they were 
utilizing Pap smears as screening for ovarian cancer (n = 4).  This was consistent with 
pervious works that found young daughters of known BRCA1/2 mutation carriers also 
mentioned the need for increased pap smears and worry over cervical cancer risk 
(Patenaude et al., 2013).   
One participant in particular noted that her motivation for undergoing 
prophylactic bilateral oopherectomy, besides being BRCA positive, was because she had 
cervical dysplasia and had never had a normal pap smear.  An additional participant 
expressed the need for early colonoscopies as well, which is yet another cancer not 
typically associated with BRCA1/2 gene mutations (Clark & Domchek, 2011). There 
needs to be increased patient education in this area.  It is unacceptable that women may 
be making life-altering or life-risking choices based on inaccurate information 
surrounding topics such as cervical cancer risk. 
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Other participant misconceptions centered on the topic of prophylactic surgery.  
Eleven participants noted that they either had or planned to have hysterectomy or 
specifically their uterus removed.  Most did not mention the need for ovary removal.  
This finding could have been because they simply failed to mention that their ovaries and 
fallopian tubes were removed or that they intended to have them removed along with 
their uterus.  However, it is still concerning that participants are unfamiliar with the 
correct surgical terms given that they will likely have or already have had surgeries.   
Some participants specifically mentioned that they were to have their uterus 
removed related to their BRCA1/2 positive status.  While there may be a slight increased 
risk for uterine cancer with BRCA1 mutation carriers in particular, the key reproductive 
organs at highest risk for cancer are still the unmentioned ovaries and fallopian tubes 
(Segev et al., 2013).  Another participant expressed that she hoped to have only her 
fallopian tubes removed and not her ovaries, despite the fact that the greatest risk for 
ovarian cancer (Clark & Domchek, 2011).   
Another responded that having an oopherectomy was not an option until after age 
45, despite the fact that she personally desired it sooner.  This is an unfortunate 
misconception, not only since patients should be able to receive the treatments they desire 
but also because guidelines state that oopherectomy should be considered as early as ages 
35 to 40 (Berliner et al., 2013; Clark & Domchek, 2011).  This was a new finding related 
to young BRCA1/2 carriers.  These results clearly demonstrate a need for future education 
of very young BRCA1/2 mutation carriers’ pertaining to the risks specific to each female 
reproductive organ.   
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Risk Reducing Mastectomy.  The data showed that all of the women who took 
part in this study (N = 63) had considered prophylactic surgery.  The main topic 
participants discussed was mastectomy (n  = 128), signifying that this is a critical topic 
for these very young mutation carriers.  Surgery related to the ovaries or uterus was 
referenced less often (n  = 72) with over half of the references having to do with 
participants wanting to wait until after they have children or were past age 30 (n  =  47).  
This indicated that, while the topic of oopherectomy is important to be aware of and plan 
for in the future for these young carriers, it is not of main concern nor will they desire 
oopherectomy in the near future.  Thus, young carriers only need to receive counseling 
and guidance regarding the salient related to oopherectomy at this age.   
Healthcare providers must keep in mind that, unlike older BRCA1/2 mutation 
carriers, emerging adults have more time to contemplate their screening and surgery 
options.  Carefully attention is needed when providing care for BRCA1/2 positive 
emerging adults to assure their autonomy and full understanding of surgical choices 
(Arnett, 2000; Werner-Lin et al., 2012).  Given the almost non-existent risk of ovarian 
cancer prior to age 30 (Stratton et al., 1999), the topic of oopherectomy is better saved for 
future healthcare appointments or sessions.  The topic of prophylactic mastectomy, on the 
other hand, is critical.     
Risk Figures.  We found that many women either overestimated their cancer risk 
(n  = 16) or quoted accurate numbers but said that they believe their actual risk for cancer 
is much higher because of their family history (n  = 16).  We also found that women often 
overestimated their risk for cancer at their current age, thinking that their current risk for 
cancer was more similar to the lifetime risks.  This overestimation of risk was supported 
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findings from previous work (Patenaude et al., 2013; Werner-Lin, 2007).  Thus, two 
recommendations were made regarding how risk figures should be discussed with BRCA 
positive emerging adults.  First, review their current age related risk for both breast and 
ovarian cancer.  The likelihood for cancer between the ages of 20 and 24 is very low, and 
patients need to know and understand this data.  It is estimated the BRCA1/2 carriers have 
a 0.02% for breast cancer and .001% for ovarian cancer (Antoniou, et al., 2003).  
However, none of the respondents quoted or mentioned that their current risk for cancer 
was this low.  Thus, this suggests that participants are not being well informed about their 
risk for cancer diagnosis specific to their young age.   
Second, participants need to be reminded that their lifetime risk for cancer is most 
accurately represented by empiric risk data for BRAC1/2 mutation carriers.  Family 
history does play an important role in determining who receives genetic testing and who 
seeks genetic testing.  However, once a person is a known carrier, there are cancer risk 
estimates available for BRCA1 or BRCA2.  At this point, patients need to be reminded 
that, typically, family history does not elevate their risk to be higher than published data.  
It would be unusual to find a BRCA1/2 mutation carrier that did not have a substantial 
family history of cancer due to the automsomal dominant nature of HBOC syndrome and 
the fact that de novo cases are very rare (Clark & Domchek, 2011).  Most participants in 
our study cited extensive family histories of cancer (n = 64).    
Common misconceptions included responses such as, “95% because both my 
grandmothers had breast cancer and my mother had both breast and ovarian cancer and 
now that I know I have a BRCA1 gene mutation I know my risk is vary high” or “I had a 
98% chance by age 30, it wasn’t an option to not be preventative [and undergo 
61 
mastectomy].”  Based on this data, we propose that time needs to be spent focusing on 
known risk numbers and reminding patients that most fellow-carriers have an extensive 
family history of cancer experiences.  An extensive cancer family history does not make 
the likelihood of cancer absolute (Werner-Lin, 2007).        
These are recommendations, and with recommendations there always come 
exceptions.  Thus, it is recommended providers inform patients that we may learn more 
about more mutation-specific risks in the future.  HBOC is a cancer predisposition 
syndrome and not an absolute cancer-causing disease.  Over time, there is hope that we 
may learn genotype-phenotype correlations do exist and that mutation-specific risk 
estimates may become available (Donnelly et al., 2013).  At the current time, it is our 
recommendation that providers offer the most up-to-data risk estimate data both for a 
patient’s current age and for over their lifetime, while encouraging patients to stay in 
touch as new data emerges in the future.      
Reproductive Options.  A large number of participants expressed their thoughts 
on reproductive issues and family planning (n  = 73).  Based on the volume of responses 
related to reproduction, we concluded that reproductive issues and family planning are 
highly relevant topic for young mutation carriers.  Healthcare providers working with 
young BRCA carriers will need to assure that they are prepared to discuss these variable 
topics.  This supported the conclusion from previous work with young BRCA1/2 carriers 
(Ormondroyd et al., 2012).  
 A minority of written responses referenced participants not yet being ready to 
think about family planning at their current life stage.  A majority discussed their 
thoughts on adoption, IVF with or without PGD, having a family the natural way, or that 
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they desired no children.  Many noted that they had at least considered these options and 
that their desires related to family planning have evolved over time.  This data proved 
that these options are of importance to most women in this age group.  Even if they are 
not ready at the current time to utilize these options, they are apart of most participants’ 
life plans.  Based on our data, and the fact that not all pregnancies are planned, we 
recommend that family planning options are presented to patients.  From their, patients 
can guide to what level of detail each option is discussed, if it at all at the current time.  
This way the seed is planted so that, in the future, education discussions can take place as 
the needs of young BRCA carriers evolve.        
As anticipated, we also saw participants express that they struggled to find a 
balance between reducing risk and losing reproductive options (Werner-Lin, 2008).  A 
common trend was planning to delay having surgeries so that they could have a family (n 
= 29).  For most, oopherectomy only was postponed until childbearing was complete.  
However, participants also brought up the desire to breastfeed their children as a primary 
reason for why they desired to delay having both mastectomy and oopherectomy.  Due to 
the variability in participant responses and desires, careful and unbiased counseling 
where these young carriers feel supported in their decisions will be essential to enabling 
full patient autonomy (Hoskins et al., 2014), as found by previous researchers as well as 
our study.      
Resource for Future.  Needs of emerging adults change over time (Arnett, 2000) 
and thus, so do their needs concerning cancer risk management (Hoskins et al., 2014).   
We propose that health care providers or genetic counselor that work with these BRCA1/2 
positive emerging adults inform these young carriers that care will extend beyond the 
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first appointment.  Young BRCA carriers who that they are positive prior to age 25 stated 
that their medical management needs and questions will change over time.  This could 
range anywhere from talking about birth control as their current mode of family planning 
to discussing the need to plan financially for IVF with or without PGD.   
There are no one-size fits all plans.  Providing young BRCA carriers the 
knowledge that they always will have a healthcare or genetics professional available to 
answer important questions that may arise is key.  Young carriers felt the most pleased 
with their care when they are supported and guided through and beyond emerging 
adulthood (Arnett, 2000; Hoskins et al., 2012; Hoskins et al., 2014).    
   2.5.4. Limitations.  Individuals were recruited via the Internet, limiting the study to 
individuals with Internet access that periodically visit BRCA-related websites or follow 
social media accounts.  Participation in this study was not limited to women only.  
However, the websites and social media used to gather participants primarily cater to a 
female audience.  Since HBOC syndrome affects primarily women, it is typical to obtain 
few to no male participants in BRCA research.  In addition, we did not obtain an 
ethnically and socioeconomically diverse sample.  Thus, findings may not generalize 
across ethnic groups, to people of different socioeconomic status, or across disease types.    
   2.5.5. Areas for Future Research.  Future research opportunities identified through the 
course of this study, which could use additional study, are listed below.    
 Targeting male participants and minority groups 
o Resources are men or minority groups using as a source of support 
and guidance, so they can used in future research efforts  
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o What these groups’ knowledge is concerning their reproductive 
health and personal cancer risk 
 Additional studies focusing on how this group is undergoing surveillance or 
planning for surgeries, since we saw significant inconsistencies in their 
established healthcare plans 
 Expanding beyond HBOC to determine the counseling needs for different 
caner disposition syndromes (Cowden syndrome, Lynch Syndrome, etc.) 
Beyond BRCA, there is much research that needs to be done on mutation carriers 
under the age of 25, but with other hereditary cancer predisposition syndromes.  There 
are more young individuals living everyday life knowing that their risk for cancers is 
significantly higher then that of the general population, without guidelines to inform them 
how they should be undergoing surveillance (Clark & Domchek, 2011). 
2.6 Conclusions 
 Our study followed in the path of previous, related works on BRCA1/2 positive 
emerging adults.  We found that participants were very satisfied with their decision to 
undergo genetic testing, with satisfaction scores of 4.7 out of 5.  Satisfaction was high 
regardless of age, life stability, or whether or not they had received genetic counseling.  
Much like these previous studies, our research found a lack of guidance, support, and 
consistent standard of care for mutation carriers who received genetic testing before age 
25 (Hoskins & Werner-Lin, 2012; Hoskins et al, 2014).  Our study was unique in the fact 
that we were successful in gathering information from a larger participant pool (N =63). 
Based on the data obtained, five suggestions were developed to guide health care 
providers and genetic professionals to better care for BRCA1/2 positive emerging adults.  
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Recommendations, or the five Rs included: (1) Reproductive Organs: Discuss which 
female reproductive organs are and are not at risk (i.e. NOT cervical cancer); (2) Risk 
Reducing Mastectomy: Primarily discuss prophylactic bilateral mastectomy, with less 
time devoted to discussing oopherectomy; (3) Risk Figures: Discuss age-specific risk 
figures and how lifetime empiric cancer risk figures are accurate for them, and hopefully 
we will have even more mutation-specific numbers in future (i.e., most BRCA1/2 positive 
women have a significant cancer family history); (4) Reproductive Options: Cover 
possible reproductive options (not all pregnancies are planned; basic knowledge can be 
critical for future or financial planning); and (5) Resource for Future: Be an educated 
future resource (Their needs and questions will change over time, be there to answer 
them).  
Participants in this emerging adult group were variable in their responses, desires, 
and medical management plans for the future.  A clear trend was that participants desired 
more clear and unbiased care and counseling, where they felt supported.  The complexity 
of HBOC plus the variable lives BRCA1/2 positive emerging adults face led us to propose 
a core set of counseling recommendations for young BRCA mutation carriers under age 
25.  Incorporating the five recommendations is essential to achieving full patient 
autonomy and unbiased decision facilitation. 
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Chapter 3. Conclusions 
 Our study followed in the path of previous, related works on BRCA1/2 positive 
emerging adults.  Much like these previous studies, our research found a lack of 
guidance, support, and consistent standard of care for mutation carriers who received 
genetic testing before age 25 (Hoskins & Werner-Lin, 2012; Hoskins et al., 2014).  Our 
study was unique in the fact that we were successful in gathering information from a 
larger participant pool (N =63) that was more geographically diverse.   We found that 
participants were very satisfied with their decision to undergo genetic testing, with 
satisfaction scores of 4.7 out of 5.  Satisfaction was high regardless of age, life stability, 
or whether or not they had received genetic counseling.   
Based on the data obtained, five suggestions were developed to guide health care 
providers and genetic professionals to better care for BRCA1/2 positive emerging adults.  
Recommendations, or the five Rs included: (1) Right Reproductive Organs: Discuss 
which female reproductive organs are and are not at risk (i.e. NOT cervical cancer), (2) 
Risk Reducing Mastectomy: Primarily discuss prophylactic bilateral mastectomy, with 
less time devoted to discussing oopherectomy, (3) Risk Figures: Discuss age-specific risk 
figures and how lifetime empiric cancer risk figures are accurate for them, and hopefully 
we will have even more mutation-specific numbers in future (i.e. most BRCA1/2 positive 
women have a significant cancer family history), (4) Reproductive Options: Cover 
possible reproductive options (Not all pregnancies are planned and basic knowledge can 
be critical for future or financial planning) (5) Resource for Future: Be an educated 
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future resource (Their needs and questions will change over time, be there to answer 
them).  
Participants in this emerging adult group were variable in their responses, desires, 
and medical management plans for the future.  A clear trend was that participants desired 
more clear and unbiased care and counseling, where they felt supported.  The complexity 
of HBOC plus the variable lives BRCA1/2 positive emerging adults face led us to propose 
a core set of counseling recommendations for young BRCA mutation carriers under age 
25.  Incorporating the five recommendations is essential to achieving full patient 
autonomy and unbiased decision facilitation. 
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Appendix A: List of Social Media Sources Contacted and/or Utilized 
Facebook 
African American Breast Cancer Research Study  
Just Ask! About Hereditary Breast and Ovarian Cancer 
(HBOC) 
BRCA1  LA FORCE: Facing Our Risk Empowered 
BRCA1 or BRCA2 Genetic Ovarian & Breast Cancer Gene Let’s Free Our BRCA Data!! 
BRCA1/BRCA2+ UK Male Breast Cancer 
BRCA Advanced 101 & 102 Male Breast Cancer Awareness 
BRCA Brotherhood  Men Against Breast Cancer 
BRCA Commons Power of Pink! Foundation 
BRCA Sisterhood  P.O.P.! Power of Pink Foundation  
BRCA Sisterhood Canada  SHARE Cancer Support 
BRCA Umbrella - The Breast & Ovarian Cancer Gene & You Sisters Network Inc. 
BRCA Gene Awareness Inc.  The Breast Cancer Site 
Breast Cancer Campaign  Think Pink Rocks 
BRCA Gene Awareness, Inc. Ulman Cancer Fund for Young Adults 
FAMILIES WHO SUPPORT BREAST CANCER SURVIVORS, Inc. Ulman Cancer Fund’s TEAM FIGHT 
FORCE: Facing Our Risk of Cancer Empowered Young Previvors 
Hereditary Breast & Ovarian Cancer (HBOC) Montreal Young Survival Coalition Bulletin Board 
HBOC Society 
Young Women's Breast Cancer Awareness Foundation 
(YWBCAF) 
Imerman Angels  
Blogs 
BRCA According to Me (ponderingprevivor.blogspot.com) 
BRCA Blog Directory (brcablogdirectory.wordpress.com) 
BRCA Sisterhood Blog (brcasisterhood.wordpress.com/the-sisterhood) 
Breaking BRCA (brcaprevivor.blogspot.com) 
Fitting into my BRCA Genes (fittingintomygenes.blogspot.com) 
My BRCA Blog (brcaandme.blogspot.com) 
My Journey With BRCA1 (brca1journey.blogspot.com) 
Previving and Thriving: My BRCA2+ Journey (previvingandthriving.com) 
PREvivor GENEration (previvorgeneration.com) 
Staying Positive, BRCA Positive (stayingpositivebrca.blogspot.com) 
Wearing My BRCA Genes (youngbrca1.wordpress.com) 
Young and BRCA1 Positive and High Heals: Making Our Genes Look Good (youngbrca1pos.blogspot.com) 
Other 
Bright Pink (Twitter) (@BeBrightPink)  HBOC Society (Newsletter) 
FORCE: Facing Our Risk of Cancer Empowered (Message Boards)   
 
 
 
73 
 
 
 
Appendix B: Templates for Correspondence with Social Media Groups 
Email Request for Hosting Research Survey 
To Whom It May Concern: 
 
Hello, my name is Sarah King and I am a second year genetic counseling student at the 
University of South Carolina.  My graduate student thesis project is on unaffected 
BRCA1 and BRCA2 gene mutation carriers under the age of 25.  The goal is to see how 
age affects the risk perception and life choices of these young individuals.  This data will 
be collected via an online survey through Survey Monkey.com.  I would love to 
potentially work with your organization to attempt to reach this population of individuals 
for my study.  
 
So you all are aware, this thesis project will undergo IRB approval though the University 
of South Carolina and poses virtually no harm or risk to participants.  In addition, I plan 
publish my research once the project is complete to help more individuals in this young 
age group in the future.  
 
Reaching enough individuals in this specific age group will be key to obtaining 
statistically significant results.   I think there is a great need for more information, since 
there is minimal literature, guidelines, or recommendations written for this age group.  
Therefore, I would sincerely appreciate your support.    
 
What I am hoping is that a letter to potential participants as well as the link to my survey 
be posted somewhere online.  This could include your website, face book page, etc.   
Wherever you think it would be best would be much appreciated.   
 
If you would like to me to call you to discuss my project, or if you need further 
information I would be more then happy to provide that for you.  I have a tentative 
written thesis proposal as well as rough drafts of all survey questions if you would like to 
look them over.   
 
Thank you so much for your consideration and I look forward to your reply, 
 
Sarah King   
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Social Media Templates Inviting Participants with Survey Link: Twitter 
Original Post:  
 
Updated Post:  
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Forum Post for FORCE Website 
Hello ladies and possibly some gentleman out there as well -  
 
I would like to invite you to take part in a graduate research study looking at BRCA1 and 
BRCA2 mutation carriers that are 18 to 24 years old.  I am a graduate student in the 
genetic counseling program at the University of South Carolina School of Medicine.  My 
study looks at the affect of age on life choices and satisfaction with the choice to have 
genetic testing for young people in this age group.   
 
To take part in the study, you would need to fill-out a survey on the choices that you have 
made, your overall satisfaction with your choice to have genetic testing, and resources 
that you use for support.  You are eligible for this study if you are 18 to 24 years old and 
have had genetic testing where you tested positive for a BRCA1 or BRCA2 gene 
mutation.  Both men and women are welcome to take part!  I encourage you all to share 
your stories as much as possible.   
 
The survey looks at themes in the life choices and decisions of individuals in this young 
age group.  If you do not wish to answer a question, please skip that question and 
continue filling out the rest of the survey.   The survey is 40 questions in length, 
including the questions pertaining to demographics such as age or education level.  To 
participate in this research please click here or follow this link: 
 
http://www.surveymonkey.com/s/8HQNVDD 
 
All responses from the surveys will be kept anonymous and confidential.  We only ask 
for your name and phone number in case you would be interested in providing more 
information at a later date over the phone.  It is not necessary that you provide this 
information.  The results of this study might be published or presented at academic 
meetings; however, participants will not be identified.  Your contact information will not 
be used for any other purposes besides a follow-up phone interview.  
 
Your participation in this study is voluntary. By completing the study, you are stating that 
you have read and understand this information. At any time, you may withdraw from the 
study by not finishing filling out the survey. 
 
Thank you for your time and consideration.  Your responses may help health care 
providers such as genetic counselors better care for young, high-risk people 18 to 24 
years of age in the future.  If you have any questions about this study, you may contact 
either myself or my faculty adviser, Karen Brooks, MS, CGC, using the contact 
information below.  If you have any questions about your rights as a study or research 
participant, you may contact the Office of Research Compliance at the University of 
South Carolina at (803)777-7095. 
 
Thank you all for your time and support!  
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Sarah 
 
Sarah E. King, B.A.   
Genetic Counselor Candidate 
sarah.elaine.king@gmail.com 
(260) 367-1889   
 
Karen Brooks, MS, CGC 
Faculty Adviser 
Karen.Brooks@uscmed.sc.edu  
(803) 545-5746 
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Facebook Message for Direct Message 
 
Hello, my name is Sarah King and I am a second year genetic counseling student at the 
University of South Carolina in the US.  My graduate student thesis project is on BRCA1 
and BRCA2 gene mutation carriers who tested positive for a BRCA1/2 gene mutation 
before the age of 25.   
 
The goal is to see how age affects the risk perception and life choices of these young 
individuals.  This data will be collected via an online survey through 
SurveyMonkey.com.  I would love to potentially work with your organization to attempt 
to reach this population of individuals for my study.  
 
So you all are aware, this thesis project will undergo IRB approval though the University 
of South Carolina and poses virtually no harm or risk to participants.  In addition, I plan 
publish my research once the project is complete to help more individuals in this young 
age group in the future.  
 
Reaching enough individuals in this specific age group will be key to obtaining 
statistically significant results.   I think there is a great need for more information, since 
there is minimal literature, guidelines, or recommendations written for this age group.  
Therefore, I would sincerely appreciate your support.    
 
What I am hoping is that a link to my survey be posted somewhere online.  This could 
include your website, Facebook page, Twitter account, etc.   Wherever you think it would 
be best would be much appreciated.  I have included sample Facebook and Twitter posts 
for you.     
 
Also, I am not sure if this was the best way to get in contact with your organization, but I 
believe it will be a good starting point.  
 
Thank you so much for your consideration and I look forward to your reply, 
 
Sarah King 
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Facebook Message for Facebook Wall 
 
Hello-  
 
My name is Sarah and I am a second year genetic counseling student from South 
Carolina. I have a special interest in women or men who are young survivors/previvors.  I 
am working on my graduate thesis and am trying to gain as much information about 
young previvors and their hopes/plans/experiences/etc. I hope you would not mind if I 
posted the link for my study. Thanks for your consideration!  
 
Also -Some of you may have already seen the link to my study-- It was tweeted by Bright 
Pink recently! 
 
Study Information:  
 
Help future young, high-risk individuals like you by participating in a research study. We 
would love to hear your personal story!  
 
We are looking for women or men who discovered that they are BRCA1 or BRCA2 
mutation positive before the age of 25 to take our online survey! You qualify for the 
study if you had genetic testing before your 25th birthday and tested positive. For more 
details and information or to participate in our research please click here:  
 
http://www.surveymonkey.com/s/8HQNVDD 
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Social Media Templates Inviting Participants with Survey Link: Facebook 
Original Post:  
Help future young, high-risk individuals like you by participating in a research study. We 
would love to hear your personal story!  
 
We are looking for women or men under the age of 25 who have undergone genetic 
testing and know that they carry a BRCA1 or BRCA2 gene mutation to take our online 
survey! For more details and information or to participate in our research please click 
here:http://www.surveymonkey.com/s/8HQNVDD 
 
Thank you all very much for you time, support, and consideration! 
 
 Updated Post:  
Help future young, high-risk individuals like you by participating in a research study.  
We would love to hear your personal story! 
 
We are looking for women or men who discovered that they are BRCA1 or BRCA2 
mutation positive before the age of 25 to take our online survey!  You qualify for the 
study if you had genetic testing before your 25th birthday and tested positive. For more 
details and information or to participate in our research please click here: 
http://www.surveymonkey.com/s/8HQNVDD 
 
Thank you all very much for you time, support, and consideration! 
 
Study Update Post:  
We would like to expand this study to anyone who found out that they are BRCA1 or 
BRCA2 positive before the age of 25. You qualify for the study if had genetic testing 
before your 25th birthday and tested positive.  
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Formal Survey Invitation to Participants 
Dear Potential Participant: 
You are invited to take part in a graduate research study looking at BRCA1 and BRCA2 
mutation carriers that received a positive BRCA1/2 genetic test result when they were 
under the age of 25. I am a graduate student in the genetic counseling program at the 
University of South Carolina School of Medicine. My study looks at the affect of age on 
life choices and satisfaction with the choice to have genetic testing for young people in 
this age group.  
 
To take part in the study, you would need to fill-out a survey on the choices that you have 
made, your overall satisfaction with your choice to have genetic testing, and resources 
that you use for support. You are eligible for this study if you were under 25 years of age 
when you had testing and if you tested positive for a BRCA1 or BRCA2 gene mutation. 
Both men and women are encouraged to take part!  
 
The survey looks at themes in the life choices and decisions of individuals in this young 
age group. If you do not wish to answer a question, please skip that question and continue 
filling out the rest of the survey. The survey is 40 questions in length, including the 
questions pertaining to demographics such as age or education level. We would love to 
hear your story! 
 
All responses from the surveys will be kept anonymous and confidential. We only ask for 
your name and phone number in case you would be interested in providing more 
information at a later date over the phone. It is not necessary that you provide this 
information. The results of this study might be published or presented at academic 
meetings; however, participants will not be identified. Your contact information will not 
be used for any other purposes besides a follow-up phone interview.  
 
Your participation in this study is voluntary. By completing the study, you are stating that 
you have read and understand this information. At any time, you may withdraw from the 
study by not finishing filling out the survey. 
 
Thank you for your time and consideration. Your responses may help health care 
providers such as genetic counselors better care for young, high-risk people 18 to 24 
years of age in the future. If you have any questions about this study, you may contact 
either myself or my faculty adviser, Karen Brooks, MS, CGC, using the contact 
information below. If you have any questions about your rights as a study or research 
participant, you may contact the Office of Research Compliance at the University of 
South Carolina at (803)777-7095. 
 
Sincerely,  
 
Sarah E. King, B.A. 
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Genetic Counselor Candidate 
University of South Carolina School of Medicine  
USC Genetic Counseling Program  
Two Medical Park, Suite 208 
Columbia, SC 29203 
sarah.elaine.king@gmail.com 
(260) 367-1889  
 
Karen Brooks, MS, CGC 
Faculty Adviser 
University of South Carolina School of Medicine 
USC Genetic Counseling Program 
Two Medical Park, Suite 208 
Columbia, SC 29203 
Karen.Brooks@uscmed.sc.edu  
(803) 545-5746 
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Appendix D:  Advice from one BRCA1/2 Positive Women to Another 
Advice from one Young, BRCA1/2 Positive Woman to Another 
I think it is amazing that you can find out. It is stressful but a blessing to know. I would hate to not know and have to 
go through cancer treatments. If you know, you can plan ahead. 
It's better to know. Then you can help prevent. 
Befriend your oncologist, hematologist, and your obgyn oncologist. They are your guides on this journey. Research 
options and ask the doctors many questions. Ask them if they were in your shoes, what would they do. 
You don't need to act on the results right away. You can do surveillance but it gets exhausting and the anxiety may 
get to you- it did for me. You can do the PBM before having children...I felt rushed to have kids and them I did my 
surgery but may have done it before in hindsight. 
I would tell them that knowing is a gift. If you have the mutation, you're probably going to find out at some point 
anyway. This way it doesn't creep up on you in the prime of your life, and you have options to massively reduce 
your risk. It's going to be scary and frustrating, and if it's positive your life and even your identity will change. Also, 
good luck. 
It's better to know, because it gives you the power to make healthy choices for yourself and your future. Why let 
yourself be blindsided down the road when you can have the comfort of knowing you are doing all the best you can 
for yourself? 
It depends on the person. 
Just take it a day at a time. Find a support group that works for you. I have a few on Facebook that have truly 
brought me through all of this. You don't have to be alone, and you aren't. It is hard for friends and family who are 
not going through it to always understand, so having a group of people who do is major. Also, research, research, 
research. You need to be your own advocate, and often times you will find yourself educating the health care 
providers. The more you know, the easier it will be! 
Don't fret. It's truly not the end of the world. Think of it as a Godsend because if you DO test positive just remember 
it doesn't mean you will end up with cancer. And if you do end up with it, you'll have caught it early enough so there 
won't be much of a problem. Just try to relax, and don't freak out. 
I would tell her to make sure she's really ready for what a positive result means. A lot of people test so they can hear 
it's negative. 
Whether it is positive or negative, it is good news. The knowledge gives you amazing power. 
Surround yourself with good literature, good people and supportive environment, be true to you, and find out your 
values, know that it's ok to be scared of the unknown. Don't take no for an answer, you know your body... Better 
than any dr 
Just as much info as possible, so they can go in armed with questions if need be. 
It’s not the end of the world and make sure that you know surgery is not the only option it was the only option i was 
given and I would have tried preventative drugs had i known about them, 
I would recommend the FORCE website. 
Think about what you will do with the information when you get it 
My decisions have always boiled down to: why not now? Is there a reason I should wait until I'm older to get a 
procedure done? You need to take everything into account when answering those questions. It's not just about the 
procedure themselves, but also very much where you are in your life at this moment and where you'd like to be in 
the immediate future. I was in an 'in-between' moment in my life. I had just ended a big part of my life and hadn't 
yet started something new. Don't feel rushed. Find the right moment. 
That there is pros and cons to being positive or negative. You can't listen to what you’re being told is your right 
option because it is your body, your right and your decision. You also can't let it control your life but now you have 
to live life to the fullest. 
You are not defined by your genes! Find your community and start learning the stories of others who have been 
through this (I tend to trust FORCE more than I trust Bright Pink). There are some incredible online communities 
out there that can support you and answer your questions. Here is one of them: 
https://www.facebook.com/groups/bravebosom/ 
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No matter what the result is, it is not a death sentence - it's a blessing. This test gives you your power back. Power 
over your health, the power to make decisions, the power to DECIDE how to live your best life. This test doesn't 
change anything about your health - if you have a mutation, it has been there since the moment you were conceived. 
BUT, this test DOES change what you can do about it. IF you have a mutation, you get to DECIDE how it will 
impact your life. You get to protect yourself and your health. 
I would say that everyone is different, but in my opinion, it is better to know either way so that you can better 
prepare for your future instead of wondering and not taking the proper preventative actions, which would only put 
him/her at a higher risk of developing cancer. It is best to know so that you know what to do about it. 
It's not really so big a deal. The risk of getting cancer is high for everyone, but if you get a positive result at least 
you will be studied regularly. Also mastectomy is not as bad as it might seem, at least I am very happy of my 
decision. 
Don’t take this as an end to your life look at it as a wake up call and do what you want to do and what you feel is 
right for you 
Knowledge is power and finding out one way or another is a positive and brave thing to do. You are taking control 
of your future and you can decide what you want to do going forward. If you do test positive for a faulty gene, do 
not rush in to making any decisions about preventative surgery. If you do decide to undergo preventative surgery, do 
as much research as possible before seeing a surgeon. 
Don't feel pressurized by the media or medical professionals into making massive decisions about your body. Only 
you, with support from your nearest and dearest, can decide what is right for you. 
No matter what the result is you may still get cancer or you may never get cancer. Look at the result as a tool to 
leading a healthier life. If it is positive, it really is so much better to know so if you ever do get cancer it can be 
caught at an early stage 
That person would strongly benefit from a little company & probably some healthy distractions. Jumping into 
education regarding their options would only overwhelm them in the meanwhile. 
Not to worry, and to only see a positive test as knowing as early as possible so you can get on the track to being 
aware of the risks 
One day at a time 
I would tell them that they will be the same person after their results as they are before and their beliefs and 
priorities should stay pretty much the same. The timeline of your life and the things you need to do to stay healthy 
may change, but your life is no less beautiful after the results than before. And knowing about a mutation is actually 
a beautiful gift because it changes you into a proactive person who can have a dramatic impact on your own future 
instead of just waiting around and wondering. It helps you make the most of your life in a way that most people 
can't. 
No matter your result, you are healthy. I have found this to be an important thought to return to as the screening 
process, the options, and the risks laid out can easily paint a picture and feeling of a health crisis. Having a support 
network is very important, as is being able to take time for yourself away from the business, the tests, and sometimes 
other people, as you need. 
I would say to just take the first month or two and let the results sink in. You will feel a lot of feelings and be very 
overwhelmed for a while, but don't make any decisions right then because you won't have enough distance to be 
objective. Once the dust settles, then you should really start researching your options. Go to a conference (like the 
Facing Our Risk of Cancer Empowered conference), reach out to support groups to talk to other women, and talk to 
a lot of doctors. You may not feel like you have time, but you also shouldn't make any decisions without being 
completely informed first. 
I recommend that everyone at genetic risk for HBOC meet with a genetic counselor, develop a family tree, and a list 
of family cancers and the ages diagnosed. I also recommend that they hear the results in person, not over the phone 
or via mail as I've heard some folks have. 
That everything will be ok and that even though positive result sucks and will probably turn your life upside down, 
it's wonderful that this option is available. Being able to take preventative measures is better than having to fight 
cancer and possibly lose your life. 
I would tell them to breathe. Knowledge is power and knowing is such a blessing. Many people will never know that 
they will get cancer. This is such a blessing to those who can know and do something about it. 
Don't start researching until you get your result, you will just freak your self out! 
I would tell them that I know how nerve-wracking it can be to wait, and that the wait will be over soon! I'd 
encourage them to do research if they are comfortable doing so, and consider the choices that they might make if 
they test positive. I'd also encourage anyone who is considering testing or waiting for results to find a community of 
people in the same boat - FORCE, Bright Pink's PinkPal program, Facebook groups like BRCA Sisterhood or 
Young Previvors are all invaluable options! 
That the mutation is not a death sentence, nor should it have a negative impact on your life. Knowing about the 
mutation is knowledge, and knowledge is such a powerful thing. It gives us the power to prevent cancer before it 
occurs, or at that very least significantly lower our risks. It allows us to be in control of our health, and life. 
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Too not worry too much until you get the result back. Once you do have the results take your time before you do 
anything and weigh all your options. 
It's a blessing to know. You are the lucky ones who have precursors and you have the ability to set your future and 
be proactive if you are positive 
Relax.  You tested for a reason.  You must have a family history.  Your surveillance will be high even if you are 
negative.  If you are positive. Welcome to the sisterhood, it won't always be easy, it won't always be cheap, and you 
won't always understand it.  But you are never along, you will din courage you never knew that you had.  You will 
have a chance to survive.  My positive is a positive.  I am positive and I know how to live the rest of my life now.   
Try to keep your routine and carry on. You can't dwell on it, it is what it is, you were born with it and it has been 
apart of you for X amount of years. Get educated and know your options and choices. FIND THE BEST 
DOCTORS!! 
No matter your result you are still you. Even if you end up positive you can still have a normal life. 
To take things slowly and take time to process everything. To think about what you will do one way or another. But 
not to freak out... Medicine is amazing and there are so many bugged things in life than BRCA. 
It is normal to be concerned, worried and anxious to get results back. Bring someone to the appointment if you can 
to help take notes or just to have a second set of ears, sometimes you don't remember everything when you are given 
life altering news. Think about the different options prior to getting results back, but don't make any quick decisions 
once you have been given positive results. 
That knowledge is empowering, whatever that knowledge is it comes with choices that you can make. It's all about 
what is right for you, so take it one-step and one day at a time and be grateful that you get to make a choice many 
women are denied. 
Listen to the opinions around you, but choose what makes you most comfortable in the end. 
Although it seems like a negative thing or burden, these results do not determine your life. The results do not change 
you, and thankfully to medical advancements there are precautionary steps to take. Do not let the result define you! 
If you are positive, be thankful you were given the chance to know, and can take preventative measures! If you are 
negative, still keep up on mammograms and self-checks, there is still family history! Live your life! 
Just think positive and you will get through this. 
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Appendix E:  Additional Results 
Satisfaction and Participant Worry.  Each participant’s level of worry or concern 
regarding finding a job, finding a place to live, completing school or duties at work, 
finding a partner or getting married, having children or family planning, or reducing the 
risk for cancer via surgeries, treatment, etc., was assessed.  An ANOVA test was 
preformed comparing each of these levels of worry or concern to the SWDS, and was not 
found to be statistically significant.  The p values ranged from p = 0.119 to p = 0.593.      
Education vs. Life Planning and Age at Time of Study.  Education level was 
compared to the three life planning choice questions and age at the time of the study (See 
Table 2.6).  A significant association was found between participant education and if they 
had received genetic counseling, χ2(4, N = 51) = 11.16, p = 0.03.  Participants were more 
likely to have had genetic counseling if they had reached a higher level in their education.  
However, this test violated the rules of Chi-square test, since there were only four 
participants total who did not have genetic counseling.    
Income vs. Life Planning and Age at Time of Study.  Most participants had a 
personal income that was between $30,001 and $50,000 (37%) (see Table 2.7).  No 
significant relationships were found between participant income and life-planning 
choices, or between participant ages at the time of the study. 
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Table 2.11. Participant educational level vs. life planning choices or age at time of study. 
  
Medical 
management 
plan in place 
Genetic 
Counseling*  
Family planning 
or reproductive 
options 
Age at time of 
study 
Education Yes No Yes  No Yes No 
Under 
25 
25 and 
Over 
Finished high school or GED 2 1 1 2 1 2 2 1 
Some college education 9 0 8 1 2 7 5 4 
Associate's degree 7 0 5 2 4 3 3 4 
Bachelor's degree 14 0 17 0 10 6 5 12 
College beyond a bachelor's 
degree 11 2 13 2 6 9 4 10 
Total 43 3 44 7 23 27 19 31 
Chi-square  
 χ2(4, N = 47) = 
4.72, p = 0.32 
 χ2(4, N = 51) = 
11.16, p = 0.03* 
  χ2(4, N = 50) = 
4.56, p = 0.34 
χ2(4, N = 50) = 
3.35, p = 0.50 
 
Table 2.12. Personal income vs. life planning choices or age at time of study. 
  
Medical 
management plan in 
place Genetic Counseling 
Family planning or 
reproductive options 
Age at time of 
study 
Personal income  Yes No Yes No Yes No 
Under 
25 
25 and 
Over 
    Less than $12,000 8 0 8 1 4 5 6 3 
   $12,0001 to $30,000 3 1 2 2 1 3 2 2 
   $30,001 to $50,000 15 1 15 2 8 9 6 10 
   $50,001 to $100,000 13 1 13 2 8 6 2 13 
   More than $100,000 1 0 2 0 0 2 0 2 
Total 40 3 40 7 21 25 16 30 
Chi-square  
  χ2(4, N = 43) = 
2.69, p = 6.11 
  χ2(4, N = 47) = 
4.50, p = 0.34 
  χ2(4, N = 46) = 
3.13, p = 0.54 
  χ2(4, N = 46) = 
8.60, p = 0.72 
 
Table 2.13.  Participant ages by group vs. life planning choices. 
  
Timeline for 
Life 
Overall Life 
Plans 
Medical 
Management 
Plan in Place 
Genetic 
Counseling 
Family Planning or 
Reproductive 
Options 
Age at time of 
study  Yes No Yes  No Yes  No Yes No Yes No 
Under 25 15 4 9 10 18 1 16 3 8 11 
25 and Over 20 11 14 17 26 5 27 4 14 16 
Total 35 15 23 27 44 6 43 7 22 27 
Chi-
Squared/Fisher's 
Exact Test 
 χ2(1, N = 50) = 
1.17, p = 0.23 
 χ2(1, N = 50) = 
0.02, p = 0.55 
 χ2(1, N = 50) = 
1.32, p = 0.5 
  χ2(1, N = 
50) = 0.08, p 
= 0.54 
  χ2(1, N = 49) = 
0.10, p = 0.49 
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Table 2.14. Participants who received genetic counseling vs. life planning.   
  Timeline for Life Overall Life Plans 
Genetic Counseling Yes No Yes  No 
Yes 33 12 23 22 
No 5 3 1 7 
 Total 38 15 24 29 
 Chi-square/Fisher’s Exact Test  X2(1, N = 53) = 0.40, p = 0.40  X2(1, N = 53) = 4.09, p = 0.47 
 
Life Stability and Genetic Testing Satisfaction.  The number of years participants 
were with their partners and the number of residency changes participants had in the past 
eight years were asked to gauge life stability.  These questions were compared to whether 
or not participants felt that their positive BRCA1/2 mutation status affected their timeline 
for life or their overall life plans.  These questions were compared using an ANOVA test.  
There was no significant effect between years with partner and timeline for life, F(1, 32) 
= 0.89, p = 0.35.  There was no significant difference between the number of years with 
partner and overall life plan, F(1, 32) = 0.46, p = 0.50.   There was no significant 
difference between number of residency changes an timeline for life, F(1, 34) = 0.16, p = 
0.70.  No significant difference between number of residency changes and overall life 
plan was found, F(1, 34) = 0.01, p = 0.92.  
Genetic testing results disclosure.  Participants were informed of their positive 
genetic test result in clinic (n = 26) or outside of clinic (n = 27).  The number of times 
participants reported specific details about their experience were counted (Table 2.15).   
A main theme among responses by participants who received their result while 
outside of clinic was recalling what they were doing or where they were at the time of 
results disclosure (n = 23).  Most participants who received their result outside of clinic 
were at home when they received the call (n = 12) and were called by a genetic counselor 
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(n = 8).  Most of the participants who received their test result in clinic also spoke to a 
genetic counselor (n = 16) and brought along family members or a significant other (7).    
One participant, who relived her result outside of clinic, wrote “I originally asked 
for my results by letter but when it came down to knowing the answer, I decided to rip it 
off like a Band-Aid and find out.  I was at work and I got a call from my genetic 
counselor (on my cell).”  Another wrote, “I was at work when I received the call.  It was 
upsetting to find out but I knew I was at risk because of my family history.”  
Table 2.15.  Genetic testing results disclosure.   
Genetic Testing Results Disclosure (n = 61) n 
Outside of clinic 27 
Cited specific details about the moment of results disclosure  23 
At home 12 
At work 5 
In the car 3 
At lunch 2 
At college 1 
Cell phone  14 
Over the phone 10 
Called by a genetic counselor 8 
Sought support from family/significant other after the news 8 
Expressed that they were upset by the result 6 
Called by doctor  4 
Follow up appointment with a doctor 4 
Previously devised a plan for results disclosure with a provider 2 
Follow up appointment with a genetic counselor 2 
Expressed that they were happy to know their result 2 
Land line phone  1 
Posted while on nursing placement  1 
Over Skype by mother - while in Japan 1 
In clinic 26 
Genetic counselor 16 
Came to appointment with family or significant other 7 
Doctor 5 
Letter in the mail 3 
Oncologist 2 
Oncologist and genetic counselor    1 
Geneticist   1 
Follow up appointment with a genetic counselor 1 
Not surprised when informed of result 8 
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One of the participants who came to clinic with her family members 
wrote: Once my mum was confirmed BRCA [mutation carrier] the 
females in my family were given the option to be tested.  We did this 
altogether and so we all went to the hospital as a family to get our 
results… my auntie and myself were positive and my sister was negative.  
It was strange: my sister was upset for me, I was upset for my auntie and 
my mum was just devastated and pleased at the same time…. Pleased for 
my sister by devastated for me and my auntie and we were all sad that 
they didn’t know about this and we could have perhaps saved my 
grandma. 
Another who was not surprised by her result wrote, “In my heart I knew I was 
positive.  I was prepared.  He [the geneticist] was most shocked when I thanked him.  He 
was concerned as at the time I was the youngest person he had to give results to in the 
clinical [HBOC] study.” 
 
